WO2003016289A1 - Triazine derivatives and their use as sunscreens - Google Patents

Triazine derivatives and their use as sunscreens Download PDF

Info

Publication number
WO2003016289A1
WO2003016289A1 PCT/EP2002/008888 EP0208888W WO03016289A1 WO 2003016289 A1 WO2003016289 A1 WO 2003016289A1 EP 0208888 W EP0208888 W EP 0208888W WO 03016289 A1 WO03016289 A1 WO 03016289A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
acid
formula
substituted
hydroxy
Prior art date
Application number
PCT/EP2002/008888
Other languages
French (fr)
Inventor
Barbara Wagner
Original Assignee
Ciba Specialty Chemicals Holding Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Specialty Chemicals Holding Inc. filed Critical Ciba Specialty Chemicals Holding Inc.
Priority to AT02772133T priority Critical patent/ATE485281T1/en
Priority to DK02772133.1T priority patent/DK1423371T3/en
Priority to JP2003521215A priority patent/JP4344241B2/en
Priority to DE60238066T priority patent/DE60238066D1/en
Priority to EP02772133A priority patent/EP1423371B1/en
Priority to US10/486,761 priority patent/US7038046B2/en
Publication of WO2003016289A1 publication Critical patent/WO2003016289A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966Triazines or their condensed derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/70Other substituted melamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to novel triazine derivatives, to a process for the preparation of such compounds and to the use of such compounds for cosmetic preparations.
  • novel triazine derivatives correspond to the formula
  • R is a -C ⁇ alkyl, C 2 -C 18 alkenyl, C 6 -C 10 aryl or C 6 -C 10 heteroaryl radical each unsubstituted or mono- or poly-substituted by hydroxy, C,-C 18 alkyl, C,-C 18 alkoxy, amino, C,-C 5 mono- alkylamino or by di-C C 5 alkylamino; C 5 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl each unsubstituted or substituted by C,-C 5 alkyl; -OR'; or -NR'R";
  • R 2 is hydrogen; a C,-C 18 alkyl, C 2 -C 18 alkenyl; C 3 -C 10 aryl or C 6 -C 10 heteroaryl radical each unsubstituted or mono- or poly-substituted by hydroxy, C,-C 18 alkyl, C,-C 18 alkoxy, cyano, amino, C,-C 5 monoalkylamino or by di-C,-C 5 alkylamino; -OR'; or -NR'R"; or
  • R, and R 2 together form a 5- to 7-membered carbocyclic or heterocyclic ring;
  • A is C,-C 5 alkyl; an unsubstituted or hydroxy-, C,-C 18 alkyl- or C,-C 18 alkoxy-substituted
  • R' and R" are each independently of the other hydrogen; unsubstituted or mono- or poly- hydroxy-, halo-, C ⁇ C ⁇ alkyl-, C,-C 18 alkoxy-, amino- or quaternary ammonium group- substituted C,-C 18 alkyl, C 5 -C 7 cycloalkyl or phenyl;
  • R 3 is hydrogen; or C,-C 6 alkyl; and n is 0 or 1.
  • C,-C 18 Alkyl denotes straight-chain or branched hydrocarbon radicals, for example methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 2-ethylbutyl, n-pentyl, isopentyl, 1 -methylpentyl, 1 ,3-dimethylbutyl, n-hexyl, 1 -methylhexyl, n-heptyl, isoheptyl, 1,1,3,3-tetra-methylbutyl, 1 -methylheptyl, 3-methylheptyl, n-octyl, 2-ethylhexyl, 1,1,3- trimethylhexyl, 1,1 ,3,3-tetramethylpentyl, nonyl, decyl, undecyl, 1 -methylundecyl, dodecyl, tri
  • C,-C 18 Alkoxy denotes straight-chain or branched radicals, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, amyloxy, isoamyloxy or tert- amyloxy, n-hexyloxy, 1 -methylhexyloxy, n-heptyloxy, isoheptyloxy, 1,1 ,3,3-tetramethyl- butoxy, 1 -methylheptyloxy, 3-methylheptyloxy, n-octyloxy, 2-ethylhexyloxy, 1,1,3-tri- methylhexyloxy, 1 ,1 ,3,3-tetramethylpentyloxy, nonyloxy, decyloxy, undecyloxy, 1 -methyl- undecyloxy, dodecyloxy, tridecyloxy, tetradecyl
  • C 2 -C 18 AIkenyl is, for example, allyl, methallyl, isopropenyl, 2-butenyl, 3-butenyl, isobutenyl, n-penta-2,4-dienyl, 3-methyl-but-2-enyl, n-oct-2-enyl, n-dodec-2-enyl, isododecenyl, n- dodec-2-enyl or n-octadec-4-enyl.
  • C 6 -C 10 Aryl is, for example, phenyl or naphthyl.
  • a heterocyclic ring is a heteroaromatic system containing at least one oxygen, sulfur and/or nitrogen hetero atom in the ring structure.
  • Preferred heteroaryl groups preferably contain from 2 to 15 carbon atoms.
  • Examples of mono- or di-C,-C 3 alkylamino are methylamino, ethylamino, propylamino, n- butylamino, sec-butylamino, tert-butylamino, pentylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino and methyl-ethylamino.
  • R, and R 2 are each independently of the other C,-C, ⁇ alkyl or phenyl each unsubstituted or substituted by C 1 -C 5 alkyl, hydroxy or by C,-C 5 alkoxy; -OR'; or -NR'R"; or R, and R 2 together form a 5- to 7-membered carbocyclic or heterocyclic ring.
  • R is C,-C 3 alkyl; C,-C 5 alkoxy; or unsubstituted or C,-C 5 alkyl-, hydroxy- or C,-C 5 alkoxy- substituted phenyl.
  • R 2 is hydrogen; C,-C 5 alkyl; C,-C 3 alkoxy; unsubstituted or hydroxy-, C C 5 alkyl- or C,-C 5 - alkoxy-substituted phenyl; and n is 1.
  • R, and R 2 together are a -(CH 2 ) 2J - radical that is not further substituted or is substituted by one or more C,-C 3 alkyl and is uninterrupted or interrupted by one or two -O- and/or -
  • R, and R 2 together are a or ,N .
  • R 5 is hydrogen; or C,-C 3 alkyl.
  • a in formula (1 ) is especially amino; phenyl; or C,-C 5 alkoxyphenyl.
  • R 3 in formula (1) is especially hydrogen. Special preference is given to compounds of formula (1) wherein R, and R 2 are C,-C 5 alkyl.
  • the triazine derivatives of formula (1) according to the invention are prepared in a manner known perse by reacting a diaminotriazine compound of formula
  • R 4 is C,-C 5 alkyl and R perpetrator R 2 , R 3 , A and n are as defined for formula (1), to form a compound of formula (1).
  • the reaction is carried out in the presence of an acid, with or without the addition of one or more solvents at a reaction temperature of from 0 to 200°C.
  • the reaction is preferably carried out in DMSO, N-methylpyrroIidone, DMF or DMA. It is also possible, however, to use protic solvents, such as ethanol, methanol, isobutanol or iso- propanol.
  • the reaction can also be carried out in an aliphatic or aromatic solvent, such as hexane, toluene or xylene. It is also possible to use ethers, such as diethyl ether and tetrahy- drofuran, or halogenated solvents, such as chloroform or dichloromethane.
  • the reaction is preferably carried out as a one-pot reaction.
  • the individual reactants may, however, be added in any desired order.
  • the catalyst may be present from the beginning or may be introduced only later. It is also possible first to start the reaction between (1 b) and (1 c) in the presence of the catalyst and only later to add the triazine compound of formula (1 a). It is equally possible first to react the compound of formula (1 a) with the compound of formula (1 b) in the presence of a catalyst and to add (1 c) later.
  • the reaction can be carried out at a temperature of from 0 to 200°C, preferably at from 20 to 100°C and especially from 50 to 80°C.
  • reaction times are dependent upon the reaction temperature. Within the preferred temperature range, the reactions are generally completed within from 1 to 6 hours. At low temperatures, the reaction time increases considerably and may be 48 hours or more.
  • catalysts there are used organic and inorganic Br ⁇ nstedt or Lewis acids or mixtures thereof.
  • typical acids are phosphoric acid, trifluoroacetic acid, oxalic acid, methanesulfonic acid, toluenesulfonic acid, phenylsulfonic acid and trifluoromethanesulfonic acid.
  • acid anhydrides for example trifluoromethanesulfonic anhydride, methanesulfonic anhydride and acetic anhydride.
  • Lewis acids such as phosphorus oxychloride, copper chlorides, zinc chloride, lanthanum chloride, chromium chlorides, iron chlorides, aluminium chloride, titanium chlorides, germanium chloride, and hydrates thereof. It is also possible to use acidic ion exchangers.
  • the product is isolated according to conventional techniques, such as filtration, centrifuga- tion, phase separation and liquid extraction.
  • the products are purified, inter alia, by recrys- tallisation from a solvent or from a solvent mixture, preference being given to solvents or solvent mixtures containing alcohols. Purification can also be carried out by chroma- tographic methods and by distillation.
  • the compounds of formula (1) according to the invention are suitable especially as UV filters, that is to say to protect organic materials that are sensitive to ultraviolet light, especially human and animal skin and hair, against the damaging effect of UV radiation.
  • the compounds are accordingly suitable as light-protective agents in cosmetic, pharmaceutical and veterinary medicine preparations.
  • the compounds can be used either in the dissolved state or in the micronised state.
  • the invention accordingly relates also to a cosmetic preparation comprising at least one compound of formula (1 ), and to cosmetically tolerable carriers or adjuvants.
  • the cosmetic preparation may also comprise one or more further UV protective substances of the following substance classes:
  • p-aminobenzoic acid derivatives for example 4-dimethylaminobenzoic acid 2- ethylhexyl ester;
  • salicylic acid derivatives for example salicylic acid 2-ethylhexyl ester
  • dibenzoylmethane derivatives for example 1 -(4-tert-butylphenyl)-3-(4-methoxyphenyl)- propane-1 ,3-dione;
  • diphenylacrylates for example 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, and 3- (benzofuranyl) 2-cyanoacrylate;
  • benzofuran derivatives especially 2-(p-aminophenyl)benzofuran derivatives, described in EP-A-582 189, US-A-5 338 539, US-A-5 518 713 and EP-A-61 3 893;
  • polymeric UV absorbers for example the benzylidene malonate derivatives described in EP-A-709 080;
  • cinnamic acid derivatives for example the 4-methoxycinnamic acid 2-ethylhexyl ester and isoamyl ester or cinnamic acid derivatives disclosed in US-A-5 601 81 1 and
  • camphor derivatives for example 3-(4'-methyl)benzylidene-boman-2-one, 3-benzyl- ideneboman-2-one, N-[2(and 4)-2-oxyborn-3-ylidene-methyl)-benzyl]acrylamide polymer, 3-(4'-trimethylammonium)-benzylidene-bornan-2-one methyl sulfate, 3,3'-(1 ,4- phenylenedimethine)-bis(7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptane-1 -methanesulfonic acid) and salts, 3-(4'-sulfo)benzylidene-boman-2-one and salts; camphorbenzalkonium methosulfate;
  • hydroxyphenyltriazine compounds for example 2-(4'-methoxyphenyl)-4,6-bis(2'- hydroxy-4'-n-octyloxyphenyl)-1,3,5-triazine; 2,4-bis ⁇ [4-(3-(2-propyloxy)-2-hydroxy- propyloxy)-2-hydroxy]-phenyl ⁇ -6-(4-methoxyphenyl)-1 ,3,5-triazine; 2,4-bis ⁇ [4-(2-ethyl- hexyloxy)-2-hydroxyJ-phenyl ⁇ -6-[4-(2-methoxyethyl-carboxyl)-phenylamino]-1 ,3,5- triazine; 2,4-bis ⁇ [4-(tris(trimethylsilyloxy-silylpropyloxy)-2-hydroxy]-phenyl ⁇ -6-(4- methoxyphenyl)-1 ,3,5-triazine; 2,4-bis ⁇ [4
  • UV absorbers described in "Sunscreens”, Eds. N.j. Lowe, N.A.Shaath, Marcel Dekker, Inc. , New York and Basle or in Cosmetics & Toiletries (107), 50ff (1992) also can be used as additional UV protective substances.
  • ETHYLHEXYL TRIAZONE benzoic acid 4,4',4"-(1,3,5-triazine-2,4,6- 88122-99-0 triyltriimino)tris-, tris(2-ethylhexyl) ester; 2,4,6-trianilino-(p-carbo-2'-ethylhexyl-1 '-oxy)- 1 ,3,5-triazine
  • PEG-25 PABA benzoic acid 4-amino-, ethyl ester, 113010-52-9 polymer with oxirane
  • DIETHYLHEXYL BUTAMIDO benzoic acid 4,4'-[[6-[[4-[[(1,1 -dimethyl- 154702-15-5 TRIAZONE ethyl)amino]carbonyl]phenyl]amino]-1 ,3,5- triazine-2,4-diyl]diimino]bis-, bis(2-ethyl- hexyl) ester
  • each of the above-mentioned light-protective agents can be used in admixture with the UV absorbers according to the invention. It will be understood in that connection that, in addition to the UV absorbers according to the invention, it is also possible for more than one of the additional light-protective agents to be used, for example, two, three, four, five or six further light- protective agents.
  • mixing ratios of UV absorbers according to the invention/further light-protective agents of from 1 :99 to 99:1, especially from 1 :95 to 95:1 and preferably from 10:90 to 90:10, based on weight.
  • mixing ratios of from 20:80 to 80:20, especially from 40:60 to 60:40 and preferably of approximately 50:50.
  • Such mixtures can be used, inter alia, to improve solubility or increase UV absorption.
  • the cosmetic preparations are suitable especially as UV filters, that is to say for the protection of organic materials that are sensitive to ultraviolet light, especially skin and hair, against the damaging effect of UV radiation.
  • the UV absorbers can be used either in the dissolved state or in the micronised state.
  • any known process suitable for the preparation of microparticles can be used for the preparation of the micronised UV absorbers, for example:
  • a hard grinding medium for example zirconium silicate and a protective surfactant or a protective polymer in water or in a suitable organic solvent;
  • a suitable solvent for example aqueous suspensions or suspensions containing organic solvents, or true solutions in water, ethanol, dichloroethane, toluene, N-methylpyrrolidone inter alia;
  • grinding apparatus for the preparation of the micronised organic UV absorbers there may be used, for example, a jet mill, ball mill, vibratory mill or hammer mill, preferably a highspeed mixing mill.
  • the grinding is preferably carried out with a grinding aid, for example an alkylated vinylpyrrolidone polymer, a vinylpyrrolidone/vinyl acetate copolymer, an acyl glu- tamate, an alkyl polyglucoside, ceteareth-25 or a phospholipid.
  • a grinding aid for example an alkylated vinylpyrrolidone polymer, a vinylpyrrolidone/vinyl acetate copolymer, an acyl glu- tamate, an alkyl polyglucoside, ceteareth-25 or a phospholipid.
  • the micronised UV absorbers so obtained usually have an average particle size that is from 0.02 to 2, preferably from 0.05 to 1.5, and more especially from 0.1 to 1.0, nm.
  • the UV absorbers can also be used dry in powder form.
  • the UV absorbers are subjected to known grinding methods, such as vacuum atomization, countercurrent spray-drying etc.. Such powders have a particle size of from 0.1 nm to 2 ⁇ m.
  • the UV absorbers can be coated with a surface-active compound prior to the pulverisation process, for example with an anionic, non-ionic or ampho- teric surfactant, e.g. a phospholipid or a known polymer, such as PVP, an acrylate etc.
  • the cosmetic preparations contain, for example, from 0.1 to 30 % by weight, preferably from 0.1 to 15 % by weight and especially from 0.5 to 10 % by weight, based on the total weight of the composition, of one or more UV absorbers and at least one cosmetically tolerable adjuvant.
  • the cosmetic preparations can be prepared by physically mixing the UV absorber(s) with the adjuvant using customary methods, for example by simply stirring together the individual components, especially by making use of the dissolution properties of already known cosmetic UV absorbers, for example OMC, salicylic acid isooctyl ester, inter alia.
  • the UV absorber can be used, for example, without further treatment, or in the micronised state, or in the form of a powder.
  • the cosmetic preparations may be, for example, creams, gels, lotions, alcoholic and aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders or ointments.
  • the preparations contain, for example, from 0.1 to 30 % by weight, preferably from 0.1 to 15 % by weight and especially from 0.5 to 10 % by weight, based on the total weight of the composition, of one or more UV absorbers, from 1 to 60 % by weight, especially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition, of at least one oil component, from 0 to 30 % by weight, especially from 1 to 30 % by weight und preferably from 4 to 20 % by weight, based on the total weight of the composition, of at least one emulsifier, from 10 to 90 % by weight, especially from 30 to 90 % by weight, based on the total weight of the composition, of water, and from 0 to 88.9 % by weight, especially from 1 to
  • oil components of oil-containing compositions e.g. oils, W/O, O/W, O/W/O and W/O/W emulsions or microemulsions
  • Guerbet alcohols based on fatty alcohols having from 6 to 18, preferably from 8 to 10, carbon atoms, esters of linear C 6 -C 24 fatty acids with linear C 3 -C 24 alcohols, esters of branched C 6 -C 13 carboxylic acids with linear C 6 -C 24 fatty alcohols, esters of linear C 6 -C 24 fatty acids with branched alcohols, especially 2-ethylhexanol, esters of hydroxycarboxylic acids with linear or branched C 6 -C 22 fatty alcohols, especially dioctyl malates, esters of linear and/or branched fatty acids with polyhydric alcohols (for example propylene glycol, dimer diol or trimer triol) and/or Guerbet alcohols,
  • polyhydric alcohols
  • Finsolv ® TN linear or branched, symmetric or asymmetric dialkyl ethers having a total of from 12 to 36 carbon atoms, especially from 12 to 24 carbon atoms, for example di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di-n-undecyl ether, di-n-dodecyl ether, n-hexyl n-octyl ether, n-octyl n- decyl ether, n-decyl n-undecyl ether, n-undecyl n-dodecyl ether, n-hexyl n-undecyl ether, di-tert-butyl ether, diisopentyl ether, di-3-ethyldecyI ether, tert-butyl n-octyl ether, is
  • That group of substances comprises the esterification products of fatty acids having from 8 to 24 carbon atoms, for example caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and technical- grade mixtures thereof (obtained, for example, in the pressure removal of natural fats and oils, in the reduction of aldehydes from Roelen's oxosynthesis or in the dimerisation of un- saturated fatty acids) with alcohols, for example, is
  • isopropyl myristate isononanoic acid C l6 -C 18 alkyl esters
  • stearic acid 2- ethylhexyl ester cetyl oleate
  • glycerol tricaprylate coconut fatty alcohol caprinate/caprylate
  • n-butyl stearate isopropyl myristate, isononanoic acid C l6 -C 18 alkyl esters, stearic acid 2- ethylhexyl ester, cetyl oleate, glycerol tricaprylate, coconut fatty alcohol caprinate/caprylate and n-butyl stearate.
  • dicarboxylic acid esters such as di-n-butyl adipate, di(2-ethylhexyl) adipate, di(2-ethylhexyl) succinate and diiso- tridecyl acetate
  • diol esters such as ethylene glycol dioleate, ethylene glycol diiso- tridecanoate, propylene glycol di(2-ethylhexanoate), propylene glycol diisostearate, propylene glycol dipelargonate, butanediol diisostearate and neopentyl glycol dicaprylate.
  • Preferred mono- or poly-ols are ethanol, isopropanol, propylene glycol, hexylene glycol, glycerol and sorbitol. It is also possible to use di- and/or tri-valent metal salts (alkaline earth metal, Al 3+ inter alia) of one or more alkylcarboxylic acids.
  • the oil components can be used in an amount of, for example, from 1 to 60 % by weight, especially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition.
  • any conventionally usable emulsifier can be used for the compositions.
  • non-ionic surfactants from the following groups:
  • polyol esters and especially polyglycerol esters for example diisostearoyl polyglyceryl-3- diisostearates, polyglyceryl-3-diisostearates, triglyceryl diisostearates, polyglyceryl-2- sesquiisostearates or polyglyceryl dimerates.
  • polyglycerol esters for example diisostearoyl polyglyceryl-3- diisostearates, polyglyceryl-3-diisostearates, triglyceryl diisostearates, polyglyceryl-2- sesquiisostearates or polyglyceryl dimerates.
  • esters based on linear, branched, unsaturated or saturated C 6 -C 22 fatty acids, rici- noleic acid and also 12-hydroxystearic acid and on glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and also polyglucosides (e.g. cellulose), for example po- lyglyceryl-2-dihydroxystea rates or polygIyceryl-2-diricinoIeates;
  • ethoxylated esters of natural derivatives for example polyethoxylated esters of hydrogenated castor oil
  • silicone oil emulsifiers for example silicone polyol
  • DE-A-1 1 65 574 and/or mixed esters of fatty acids having from 6 to 22 carbon atoms, methylglucose and polyols, preferably glycerol or polyglycerol, for example polyglyceryl- 3-glucose distearates, polyglyceryl-3-glucose dioleates, methyl glucose dioleates or dico- coyl pentaerythryl distearyl citrates and also
  • the addition products of ethylene oxide and/or of propylene oxide with fatty alcohols, fatty acids, alkylphenols, glycerol mono- and di-esters and also sorbitan mono- and di-esters of fatty acids, or with castor oil, are known, commercially available products. They are usually homologue mixtures, the average degree of alkoxylation of which corresponds to the ratio of the amounts of ethylene oxide and/or propylene oxide and substrate with which the ad- dition reaction is carried out.
  • C, 2 -C, s fatty acid mono- and di-esters of addition products of ethylene oxide with glycerol are known, for example, from DE-A-2 024 051 as fat-restoring substances for cosmetic preparations.
  • C 8 -C 18 Alkyl-mono- and -oligo-glycosides their preparation and their use are known from the prior art. They are prepared especially by reacting glucose or oligosaccharides with primary alcohols having from 8 to 18 carbon atoms.
  • Suitable glycoside radicals include mono- glycosides in which a cyclic sugar radical is glycosidically bonded to the fatty alcohol and also oligomeric glycosides having a degree of oligomerisation of up to preferably about 8. The degree of oligomerisation is a statistical average value based on a homologue distribution customary for such technical-grade products.
  • zwitterionic surfactants denotes especially surface-active compounds that carry at least one quaternary ammonium group and at least one carboxylate and/or sulfonate group in the molecule.
  • Zwitterionic surfactants that are especially suitable are the so-called betaines, such as N-alkyl- N,N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N,N-dimethylammonium glycinates, for example cocoacylaminopropyl- dimethylammonium glycinate, and 2-a!kyl-3-carboxymethyl-3-hydroxyethylimidazolines each having from 8 to 18 carbon atoms in the alkyl or acyl group and also cocoacylamino- ethylhydroxyethylcarboxymethylglycinate.
  • betaines such as N-alkyl- N,N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N,N-dimethylammonium glycinates, for
  • ampholytic surfactants are to be understood as meaning especially those which, in addition to containing a C 8 -C 18 -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -S0 3 H group in the molecule and are capable of forming internal salts.
  • ampholytic surfactants include N- alkylglycines, N-alkylpropionic acids, N-aikylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids, each having approximately from 8 to 18 carbon atoms in the alkyl group.
  • Ampholytic surfactants to which special preference is given are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C 12 -C, 8 - acylsarcosine.
  • ampholytic emulsifiers there also come into consideration quaternary emulsifiers, special preference being given to those of the esterquat type, preferably methyl-quaternised di-fatty acid triethanolamine ester salts.
  • Non-ionic emulsifiers are preferred. Of the non-ionic emulsifiers mentioned, special preference is given to ethoxylated fatty alcohols having from 8 to 22 carbon atoms and from 4 to 30 EO units.
  • the emulsifiers may be used in an amount of, for example, from 1 to 30 % by weight, especially from 4 to 20 % by weight and preferably from 5 to 10 % by weight, based on the total weight of the composition. It is, however, also possible in principle to dispense with the use of emulsifiers.
  • the preparations according to the invention may in addition contain, as further adjuvants and additives, mild surfactants, super-fatting agents, pearlescent waxes, consistency regulators, thickeners, polymers, silicone compounds, fats, waxes, stabilisers, biogenic active ingredients, deodorising active ingredients, anti-dandruff agents, film formers, swelling agents, further UV light-protective factors, antioxidants, hydrotropic agents, preservatives, insect repellents, self-tanning agents, solubilisers, perfume oils, colourants, bacteria-inhibiting agents and the like.
  • mild surfactants super-fatting agents
  • pearlescent waxes consistency regulators, thickeners, polymers, silicone compounds, fats, waxes, stabilisers, biogenic active ingredients, deodorising active ingredients, anti-dandruff agents, film formers, swelling agents, further UV light-protective factors, antioxidants, hydrotropic agents, preservatives, insect repellents, self-tanning agents, solubilisers, perfume oils,
  • Substances suitable for use as super-fatting agents are, for example, lanolin and lecithin and also polyethoxylated or acrylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides, the latter simultaneously acting as foam stabilisers.
  • Suitable mild surfactants include fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, mono- and/or di-alkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides, fatty acid glutamates, ⁇ -olefin sulfonates, ether carboxylic acids, alkyl oligogluco- sides, fatty acid glucamides, alkylamidobetaines and/or protein fatty acid condensation products, the latter preferably being based on wheat proteins.
  • alkylene glycol esters especially ethylene glycol distearate
  • fatty acid alkanolamides especially coco fatty acid di- ethanolamide
  • partial glycerides especially stearic acid monoglyceride
  • fatty substances for example fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which in total have at least 24 carbon atoms, especially laurone and distearyl ether
  • fatty acids such as stearic acid, hydroxystearic acid or behenic acid, ring-opening products of olefin epoxides having from 12 to 22 carbon atoms with fatty alcohols having from 12 to 22 carbon atoms and/or polyo
  • fatty alcohols or hydroxy fatty alcohols having from 12 to 22 carbon atoms and preferably from 16 to 18 carbon atoms, and in addition partial glycerides, fatty acids and hydroxy fatty acids.
  • Suitable thickeners include, for example, Aerosil types (hydrophilic silicic acids), polysaccha- rides, especially xanthan gum, guar-guar, agar-agar, alginates and Tyloses, carboxymethyl cellulose and hydroxymethyl cellulose, also relatively high molecular weight polyethylene glycol mono- and di-esters of fatty acids, polyacrylates (e.g.
  • surfactants for example ethoxylated fatty acid glycerides, esters of fatty acids with polyols, for example pentaerythritol or trimethylolpropane
  • fatty alcohol ethoxylates with restricted homologue distribution and alkyl-oligoglucosides as well as electrolytes, such as sodium chloride or ammonium chloride.
  • Suitable cationic polymers are, for example, cationic cellulose derivatives, for example a qua- temised hydroxymethyl cellulose obtainable under the name Polymer JR 400 ® from Amer- chol, cationic starch, copolymers of diallylammonium salts and acrylamides, quaternised vi- nylpyrrolidone/vinyl imidazole polymers, for example Luviquat ® (BASF), condensation products of polyglycols and amines, quaternised collagen polypeptides, for example lauryldimo- nium hydroxypropyl hydrolyzed collagen (Lamequat ® L/Gr ⁇ nau), quaternised wheat polypeptides, polyethyleneimine, cationic silicone polymers, for example amidomethicones, co- polymers of adipic acid and dimethylaminohydroxypropyldiethylenetriamine (Car- taretin ® /Sandoz), copolymers of
  • anionic, zwitterionic, amphoteric and non-ionic polymers there come into consideration, for example, vinyl acetate/crotonic acid copolymers, vinylpyrrolidone/vinyl acrylate copolymers, vinyl acetate/butyl maleate/isobomyl acrylate copolymers, methyl vinyl ether/maleic anhydride copolymers and esters thereof, uncrosslinked polyacrylic acids and polyacrylic acids crosslinked with polyols, acrylamidopropyltrimethylammonium chloride/acrylate copolymers, octyl acrylamide/methyl methacrylate/tert-butylaminoethyl methacrylate/2- hydroxypropyl methacrylate copolymers, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, vinylpyrrolidone/dimethylaminoethyl methacrylate/vinyl caprolactam
  • Suitable silicone compounds are, for example, dimethylpolysiloxanes, methylphenyl- polysiloxanes, cyclic silicones, and also amino-, fatty acid-, alcohol-, polyether-, epoxy-, fluorine-, glycoside- and/or alkyl-modified silicone compounds, which at room temperature may be in either liquid or resinous form.
  • simethicones which are mixtures of dimethicones having an average chain length of from 200 to 300 dimethylsiloxane units with hydrogenated silicates.
  • Typical examples of fats are glycerides, and as waxes there come into consideration, inter alia, beeswax, camauba wax, candelilla wax, montan wax, paraffin wax, hydrogenated castor oils and fatty acid esters or microwaxes solid at room temperature optionally in combination with hydrophilic waxes, e.g. cetylstearyl alcohol or partial glycerides.
  • Hydrophilic waxes e.g. cetylstearyl alcohol or partial glycerides.
  • Metal salts of fatty acids for example magnesium, aluminium and/or zinc stearate or ricinoleate, may be used as stabilisers.
  • Biogenic active ingredients are to be understood as meaning, for example, tocopherol, to- copherol acetate, tocopherol palmitate, ascorbic acid, deoxyribonucleic acid, retinol, bis- abolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudocera- mides, essential oils, plant extracts and vitamin complexes.
  • deodorising active ingredients there come into consideration, for example, anti- perspirants, for example aluminium chloro hydrates (see J. Soc. Cosm. Chem. 24, 281 (1973)). Under the trade mark Locron ® of Hoechst AG, Frankfurt (FRG), there is available commercially, for example, an aluminium chlorohydrate corresponding to formula AI 2 (OH) 5 CI x 2.5 H 2 0, the use of which is especially preferred (see J. Pharm. Pharmacol. 26, 531 (1975)). Besides the chlorohydrates, it is also possible to use aluminium hydroxy- acetates and acidic aluminium/zirconium salts. Esterase inhibitors may be added as further deodorising active ingredients.
  • Such inhibitors are preferably trialkyl citrates, such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate and especially triethyl citrate (Hydagen ® CAT, Henkel KGaA, D ⁇ sseldorf/FRG), which inhibit enzyme activity and hence reduce odour formation.
  • trialkyl citrates such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate and especially triethyl citrate (Hydagen ® CAT, Henkel KGaA, D ⁇ sseldorf/FRG), which inhibit enzyme activity and hence reduce odour formation.
  • esterase inhibitors are sterol sulfates or phosphates, for example lanosterol, cholesterol, campesterol, stigmasterol and sitosterol sulfate or phosphate, dicarboxylic acids and esters thereof, for example glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid and malonic acid diethyl ester and hydroxycarboxylic acids and esters thereof, for example citric acid, malic acid, tar- taric acid or tartaric acid diethyl ester.
  • dicarboxylic acids and esters thereof for example glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid
  • Antibacterial active ingredients that influence the mi- crobial flora and kill or inhibit the growth of sweat-decomposing bacteria can likewise be present in the preparations (especially in stick preparations). Examples include chitosan, phenoxyethanol and chlorhexidine gluconate. 5-Chloro-2-(2,4-dichlorophenoxy)-phenol (Ir- gasan ® , Ciba Specialty Chemicals Inc.) has also proved especially effective.
  • Customary film formers include, for example, chitosan, microcrystalline chitosan, quaternised chitosan, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, polymers of quaternary cellulose derivatives containing a high proportion of acrylic acid, collagen, hyaluronic acid and salts thereof and similar compounds.
  • swelling agents for aqueous phases there may be used montmorillonites, clay mineral substances, Pemulen and also alkyl-modified types of Carbopol (Goodrich). Further suitable polymers and swelling agents can be found in the review by R. Lochhead in Cosm. Toil. 108, 95 (1993).
  • antioxidants are amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides, such as D,L- carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotinoids, carotenes (e.g.
  • thioredoxin glutathione, cysteine, cystine, cys- tamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl, lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters thereof) and also salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and also sulfoximine compounds (e.g.
  • buthionine sulfoximines homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, hepta-thionine sulfoximine
  • very small tolerable amounts e.g. from pmol to ⁇ mol/kg
  • metal chelating agents e.g. ⁇ -hydroxy fatty acids, palmitic acid phytic acid, lactofer- rin
  • ⁇ -hydroxy acids e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof
  • unsaturated fatty acids and derivatives thereof e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and derivatives thereof ubiquinone and ubiquinol and derivatives thereof
  • vitamin C and derivatives e.g. ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g. vitamin E acetate
  • vitamin A and derivatives e.g.
  • vitamin A palmitate and also coniferyl benzoate of benzoin resin, rutinic acid and derivatives thereof, ⁇ -glycosylrutin, ferulic acid, furfurylidene glucitol, camosine, butyl hydroxytoluene, butyl hydroxyanisole, resinous nordihydroguaiaretic acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, superoxide dismutase, N- [3-(3,5-di-tert-butyI-4-hydroxyphenyl)propionyl]sulfaniIic acid (and salts thereof, for example the disodium salts), zinc and derivatives thereof (e.g.
  • ZnO, ZnSO selenium and derivatives thereof (e.g. selenium methionine), stilbene and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of those mentioned active ingredients.
  • HALS "Hindered Amine Light Stabilizers" compounds may also be mentioned.
  • the amount of antioxidants present is usually from 0.001 to 30 % by weight, preferably from 0.01 to 3 % by weight, based on the weight of the UV absorber(s).
  • hydrotropic agents for example ethanol, isopropyl alcohol or polyols.
  • the polyols that come into consideration for that purpose have preferably from 2 to 15 carbon atoms and at least two hydroxy groups.
  • the polyols may also contain further functional groups, especially amino groups, and/or may be modified with nitrogen. Typical examples are as follows:
  • alkylene glycols for example ethylene glycol, diethylene glycol, propylene glycol, buty- lene glycol, hexylene glycol and also polyethylene glycols having an average molecular weight of from 100 to 1000 dalton;
  • - technical oligoglycerol mixtures having an intrinsic degree of condensation of from 1 .5 to 10, for example technical diglycerol mixtures having a diglycerol content of from 40 to 50 % by weight;
  • - methylol compounds such as, especially, trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol and dipentaerythritol;
  • alkyl-glucosides especially those having from 1 to 8 carbon atoms in the alkyl radical, for example methyl and butyl glucoside;
  • - sugar alcohols having from 5 to 12 carbon atoms, for example sorbitol or mannitol;
  • sugars having from 5 to 12 carbon atoms, for example glucose or saccharose;
  • dialcohol amines such as diethanolamine or 2-amino-1 ,3-propanediol.
  • Suitable preservatives include, for example, phenoxyethanol, formaldehyde solution, Para- bens, pentanediol or sorbic acid and the further substance classes listed in Schedule 6, Parts A and B of the Cosmetics Regulations.
  • Natural aromatic substances are, for example, extracts from blossom (lilies, lavender, roses, jasmine, neroli, ylang-ylang), from stems and leaves (geranium, patchouli, petit- grain), from fruit (aniseed, coriander, carraway, juniper), from fruit peel (bergamot, lemons, oranges), from roots (mace, angelica, celery, cardamom, costus, iris, calmus), from wood (pinewood, sandalwood, guaiacum wood, cedarwood, rosewood), from herbs and grasses (tarragon, lemon grass, sage, thyme), from needles and twigs (spruce, pine, Scots pine, mountain pine), from resins and balsams (galbanum, elemi, benzoin, myrrh, olibanum, opoponax).
  • Animal raw materials also come into consideration, for example c
  • Aromatic substance compounds of the ester type are, for example, benzyl acetate, phe- noxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethyl- benzylcarbinyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethylmethyl- phenyl glycinate, allylcyclohexyl propionate, styrallyl propionate and benzyl salicylate.
  • the ethers include, for example, benzyl ethyl ether;
  • the aldehydes include, for example, the linear alkanals having from 8 to 18 hydrocarbon atoms, citral, citronellal, citronellyl oxyacetal- dehyde, cyclamen aldehyde, hydroxycitronellal, lilial and bourgeonal;
  • the ketones include, for example, the ionones, ⁇ -isomethylionone and methyl cedryl ketone;
  • the alcohols include, for example, anethol, citronellol, eugenol, isoeugenol, geraniol, linalool, phenyl ethyl alcohol and terpinol; and
  • the hydrocarbons include mainly the terpenes and balsams.
  • Ethereal oils of relatively low volatility which are chiefly used as aroma components, are also suitable as perfume oils, e.g. sage oil, camomile oil, clove oil, melissa oil, oil of cinnamon leaves, lime blossom oil, juniper berry oil, vetiver oil, olibanum oil, gal- banum oil, labolanum oil and lavandin oil.
  • bacteria-inhibiting agents are preservatives that have a specific action against gram-positive bacteria, such as 2,4,4'-trichIoro-2'-hydroxydiphenyl ether, chlor- hexidine (1,6-di(4-chlorophenyl-biguanido)hexane) or TCC (3,4,4'-trichlorocarbanilide).
  • gram-positive bacteria such as 2,4,4'-trichIoro-2'-hydroxydiphenyl ether, chlor- hexidine (1,6-di(4-chlorophenyl-biguanido)hexane) or TCC (3,4,4'-trichlorocarbanilide).
  • TCC 3,4,4'-trichlorocarbanilide
  • a large number of aromatic substances and ethereal oils also have antimicrobial properties.
  • Typical examples are the active ingredients eugenol, menthol and thymol in clove oil, mint oil and thyme oil.
  • a natural deodorising agent of interest is the terpene alcohol farnesol (3,7,1 1 -trimethyl-2,6,10-dodecatrien-1 -ol), which is present in lime blossom oil.
  • Glycerol monolaurate has also proved to be a bacteriostatic agent.
  • the amount of the additional bacteria-inhibiting agents present is usually from 0.1 to 2 % by weight, based on the solids content of the preparations.
  • the cosmetic preparations may contain, as adjuvants, anti-foams, such as silicones, structurants, such as maleic acid, solubilisers, such as ethylene glycol, propylene glycol, glycerol or diethylene glycol, opacifiers, such as latex, styrene/PVP or sty- rene/acrylamide copolymers, complexing agents, such as EDTA, NTA, ⁇ -alaninediacetic acid or phosphonic acids, propellants, such as propane/butane mixtures, N 2 0, dimethyl ether, CO 2 , N 2 or air, so-called coupler and developer components as oxidation dye precursors, reducing agents, such as thioglycolic acid and derivatives thereof, thiolactic acid, cysteamine, thiomalic acid or ⁇ -mercaptoethanesulfonic acid, or oxidising agents, such as hydrogen peroxide, potassium bromate or sodium bro
  • insect repellents for example, N,N-diethyl-m-toluamide, 1 ,2-pentanediol or insect repellent 3535;
  • suitable self-tanning agents are, for example, di- hydroxyacetone, erythrulose or mixtures of dihydroxyacetone and erythrulose.
  • Cosmetic formulations according to the invention are contained in a wide variety of cosmetic preparations. There come into consideration, for example, especially the following preparations: skin-care preparations, e.g. skin-washing and cleansing preparations in the form of tablet-form or liquid soaps, synthetic detergents or washing pastes, bath preparations, e.g. liquid (foam baths, milks, shower preparations) or solid bath preparations, e.g. bath cubes and bath salts; skin-care preparations, e.g. skin emulsions, multi-emulsions or skin oils; cosmetic personal care preparations, e.g.
  • skin-care preparations e.g. skin-washing and cleansing preparations in the form of tablet-form or liquid soaps, synthetic detergents or washing pastes
  • bath preparations e.g. liquid (foam baths, milks, shower preparations) or solid bath preparations, e.g. bath cubes and bath salts
  • skin-care preparations e.g. skin emul
  • eye-care preparations e.g. eyeshadow preparations, mascara, eyeliner, eye creams or eye-fix creams
  • lip-care preparations e.g. lipsticks, lip gloss, lip contour pencils
  • nail-care preparations such as nail varnish, nail varnish removers, nail hardeners or cuticle removers
  • foot-care preparations e.g.
  • foot baths foot powders, foot creams or foot balsams, special deodorants and antiperspirants or callus-removing preparations
  • light-protective preparations such as sun milks, lotions, creams or oils, sunblocks or tropicals, pre-tanning preparations or after-sun preparations
  • skin-tanning preparations e.g. self-tanning creams
  • depigmenting preparations e.g. preparations for bleaching the skin or skin-lightening preparations
  • insect-repellents e.g.
  • insect-repellent oils lotions, sprays or sticks
  • deodorants such as deodorant sprays, pump-action sprays, deodorant gels, sticks or roll-ons
  • antiperspirants e.g. antiperspirant sticks, creams or roll-ons
  • preparations for cleansing and caring for blemished skin e.g. synthetic detergents (solid or liquid), peeling or scrub preparations or peeling masks
  • shaving preparations e.g.
  • fragrance preparations e.g. fragrances (eau de Cologne, eau de toilette, eau de perfume, perfume de toilette, perfume), perfume oils or perfume creams
  • cosmetic hair-treatment preparations e.g. hair-washing preparations in the form of shampoos and conditioners, hair-care preparations, e.g. pretreatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair-structuring preparations, e.g.
  • hair-waving preparations for permanent waves hot wave, mild wave, cold wave
  • hair-straightening preparations liquid hair- setting preparations
  • hair foams hairsprays
  • bleaching preparations e.g. hydrogen peroxide solutions, lightening shampoos, bleaching creams, bleaching powders, bleaching pastes or oils, temporary, semi-permanent or permanent hair colourants, preparations containing self-oxidising dyes, or natural hair colourants, such as henna or camomile.
  • liquid preparations as a W/O, O/W, O/W/O, W/O/W or PIT emulsion and all kinds of microemulsions,
  • cosmetic preparations for the skin are light-protective preparations, such as sun milks, lotions, creams, oils, sunblocks or tropicals, pretanning preparations or after-sun preparations, also skin-tanning preparations, for example self-tanning creams.
  • light-protective preparations such as sun milks, lotions, creams, oils, sunblocks or tropicals
  • pretanning preparations or after-sun preparations also skin-tanning preparations, for example self-tanning creams.
  • sun protection creams, sun protection lotions, sun protection oils, sun protection milk and sun protection preparations in the form of a spray are particularly useful for sun protection cream.
  • hair-washing preparations in the form of shampoos, hair conditioners, hair-care preparations, e.g. pretreatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair- straightening preparations, liquid hair-setting preparations, hair foams and hairsprays.
  • hair-washing preparations in the form of shampoos.
  • a shampoo has, for example, the following composition: from 0.01 to 5 % by weight of a UV absorber according to the invention, 12.0 % by weight of sodium laureth-2-sulfate, 4.0 % by weight of cocamidopropyl betaine, 3.0 % by weight of sodium chloride, and water ad 100%.
  • hair-cosmetic formulations may be used: a,) spontaneously emulsifying stock formulation, consisting of the UV absorber according to the invention, PEG-6-C 10 oxoalcohol and sorbitan sesquioleate, to which water and any desired quaternary ammonium compound, for example 4 % minkamidopropyl dimethyl-2-hydroxyethylammonium chloride or Quaternium 80 is added; a 2 ) spontaneously emulsifying stock formulation consisting of the UV absorber according to the invention, tributyl citrate and PEG-20-sorbitan monooleate, to which water and any desired quaternary ammonium compound, for example 4 % minkamidopropyl dimethyl-2-hydroxyethylammonium chloride or Quaternium 80 is added; b) Quat-doped solutions of the UV absorber according to the invention in butyl triglycol and tributyl citrate; c) mixtures or
  • the cosmetic preparation according to the invention is distinguished by excellent protection of human skin against the damaging effect of sunlight.
  • percentages relate to weight.
  • the amounts of the triazine derivatives used relate to the pure substance.
  • 0.1 ml of trifluoromethanesulfonic anhydride is added, at 90°C , to a solution of 7.5 g (0.05 mol) of orthoformic acid triethyl ester in 50 ml of isobutanol.
  • 2.3 g (0.0125 mol) of 2,2-diamino-6-phenyl-1 ,3,5-triazine are then introduced in portions in the course of 1.5 hours.
  • the resulting solution is stirred for 30 minutes at 100 °C.
  • the reaction mixture is maintained at reflux for 4 hours. After cooling to room temperature, the suspension is filtered.
  • 2,4-Diamino-6-phenyl-1 ,3,5-triazine (0.0013 mol, 0.24 g) is dissolved in N-methylpyrroIidone (1.15 ml).
  • Orthoformic acid trimethyl ester (0.0038 mol, 0.42 ml)
  • copper chloride dihydrate solution (0.001 3 mol, 0.22 g in 0.5 ml of NMP)
  • the appropriate ketone (0.0038 mol dissolved in 2 ml of NMP) are added to the solution.
  • the reaction mixture is shaken for 4 hours at 70°C.
  • the crude product is precipitated by the addition of 10 ml of 10 % aqueous sodium sulfate solution, and the precipitate is then filtered off and washed with copious amounts of ethanol. Subsequent column chromatography (Nucleosil 5C18) using a mixture of acetonitrile and water yields the pure product.
  • the crude product is precipitated by the addition of 10 ml of 10 % aqueous sodium sulfate solution, and the precipitate is then filtered off and washed with copious amounts of ethanol. Subsequent column chromatography (Nucleosil 5C18)) using a mixture of acetonitrile and water yields the pure product.
  • Example 1 Sprayable Sunscreen Lotion
  • This emulsion contains a combination of insoluble UV-absorber.
  • the choice of emollients provides quick absorption and smooth after skin feeling.
  • Example 14 O/W emulsion water resistant
  • This emulsion is smooth and spreads easily.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There are described triazine derivatives of formula (1), wherein R1 is an unsubstituted or mono- or poly-hydroxy-, C1-C18 alkyl-, C1-C18 alkoxy-, amino-, C1-C5 monoalkylamino- or di-C1-C5 alkylamino-substituted C1-C18 alkyl, C2-C18 alkenyl, C6-C10 aryl or C6-C10 heteroaryl radical; unsubstituted or C1-C5 alkyl-substituted C5-C7 cycloalkyl or C5-C7 cycloalkenyl; -OR'; or -NR'R'; R2 is hydrogen; an unsubstituted or mono- or poly-hydroxy-, C1-C18 alkoxy-, cyano-, amino, C1-C5 monoalkylamino- or di-C1-C5 alkylamino-substituted C1-C18 alkyl, C2-C18 alkenyl; C6-C10 aryl or C6-C10 heteroaryl radical; -OR'; or -NR'R'; or R1 and R2 together form a 5- to 7-membered carbocyclic or heterocyclic ring; A is C1-C5 alkyl; an unsubstituted or hydroxy-, C1-C18 alkyl- or C1-C18 alkoxy-substituted C6-C10 aryl or heteroaryl radical; or a radical of formula (1a); R' and R' are each independently of the other hydrogen; unsubstituted or mono- or poly-hydroxy-, halo-, C1-C18 alkyl-, C1-C18 alkoxy-, amino- or quaternary ammonium group-substituted C1-C18 alkyl, C5-C7 cycloalkyl or phenyl; R3 is hydrogen; or C1-C6 alkyl; and n is 0 or 1. The compounds according to the invention are suitable especially as sun protective agents in cosmetic, pharmaceutical and veterinary medicine preparations.

Description

TRIAZINE DERIVATIVES AND THEIR USE AS SUNSCREENS
The present invention relates to novel triazine derivatives, to a process for the preparation of such compounds and to the use of such compounds for cosmetic preparations.
The novel triazine derivatives correspond to the formula
Figure imgf000002_0001
wherein
R, is a -C^alkyl, C2-C18alkenyl, C6-C10aryl or C6-C10heteroaryl radical each unsubstituted or mono- or poly-substituted by hydroxy, C,-C18alkyl, C,-C18alkoxy, amino, C,-C5mono- alkylamino or by di-C C5alkylamino; C5-C7cycloalkyl or C5-C7cycloalkenyl each unsubstituted or substituted by C,-C5alkyl; -OR'; or -NR'R";
R2 is hydrogen; a C,-C18alkyl, C2-C18alkenyl; C3-C10aryl or C6-C10heteroaryl radical each unsubstituted or mono- or poly-substituted by hydroxy, C,-C18alkyl, C,-C18alkoxy, cyano, amino, C,-C5monoalkylamino or by di-C,-C5alkylamino; -OR'; or -NR'R"; or
R, and R2 together form a 5- to 7-membered carbocyclic or heterocyclic ring;
A is C,-C5alkyl; an unsubstituted or hydroxy-, C,-C18alkyl- or C,-C18alkoxy-substituted
C6-C,0aryl or C6-C10heteroaryl radical; or a radical of formula (1 a)
Figure imgf000002_0002
R' and R" are each independently of the other hydrogen; unsubstituted or mono- or poly- hydroxy-, halo-, C^C^alkyl-, C,-C18alkoxy-, amino- or quaternary ammonium group- substituted C,-C18alkyl, C5-C7cycloalkyl or phenyl;
R3 is hydrogen; or C,-C6alkyl; and n is 0 or 1.
C,-C18Alkyl denotes straight-chain or branched hydrocarbon radicals, for example methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 2-ethylbutyl, n-pentyl, isopentyl, 1 -methylpentyl, 1 ,3-dimethylbutyl, n-hexyl, 1 -methylhexyl, n-heptyl, isoheptyl, 1,1,3,3-tetra-methylbutyl, 1 -methylheptyl, 3-methylheptyl, n-octyl, 2-ethylhexyl, 1,1,3- trimethylhexyl, 1,1 ,3,3-tetramethylpentyl, nonyl, decyl, undecyl, 1 -methylundecyl, dodecyl, tridecyl, tetradecyl, pentadecyl or hexadecyl or octadecyl.
C,-C18Alkoxy denotes straight-chain or branched radicals, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, amyloxy, isoamyloxy or tert- amyloxy, n-hexyloxy, 1 -methylhexyloxy, n-heptyloxy, isoheptyloxy, 1,1 ,3,3-tetramethyl- butoxy, 1 -methylheptyloxy, 3-methylheptyloxy, n-octyloxy, 2-ethylhexyloxy, 1,1,3-tri- methylhexyloxy, 1 ,1 ,3,3-tetramethylpentyloxy, nonyloxy, decyloxy, undecyloxy, 1 -methyl- undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, pentadecyloxy, hexadecyloxy or octa- decyloxy.
C2-C18AIkenyl is, for example, allyl, methallyl, isopropenyl, 2-butenyl, 3-butenyl, isobutenyl, n-penta-2,4-dienyl, 3-methyl-but-2-enyl, n-oct-2-enyl, n-dodec-2-enyl, isododecenyl, n- dodec-2-enyl or n-octadec-4-enyl.
C6-C10Aryl is, for example, phenyl or naphthyl.
A heterocyclic ring is a heteroaromatic system containing at least one oxygen, sulfur and/or nitrogen hetero atom in the ring structure. Preferred heteroaryl groups preferably contain from 2 to 15 carbon atoms.
Examples of mono- or di-C,-C3alkylamino are methylamino, ethylamino, propylamino, n- butylamino, sec-butylamino, tert-butylamino, pentylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino and methyl-ethylamino. Preference is given to triazine derivatives of formula (1) wherein
R, and R2 are each independently of the other C,-C,βalkyl or phenyl each unsubstituted or substituted by C1-C5alkyl, hydroxy or by C,-C5alkoxy; -OR'; or -NR'R"; or R, and R2 together form a 5- to 7-membered carbocyclic or heterocyclic ring.
More especially preferred are compounds of formula (1 ) wherein
R, is C,-C3alkyl; C,-C5alkoxy; or unsubstituted or C,-C5alkyl-, hydroxy- or C,-C5alkoxy- substituted phenyl.
Also preferred are compounds of formula (1 ) wherein
R2 is hydrogen; C,-C5alkyl; C,-C3alkoxy; unsubstituted or hydroxy-, C C5alkyl- or C,-C5- alkoxy-substituted phenyl; and n is 1.
Preference is also given to compounds of formula (1) wherein
R, and R2 together are a -(CH2)2J- radical that is not further substituted or is substituted by one or more C,-C3alkyl and is uninterrupted or interrupted by one or two -O- and/or -
NH- groups and/or — c — .
II o
Very special preference is given to compounds of formula (1) wherein
R, and R2 together are a or ,N .
Figure imgf000004_0001
radical;
R5 is hydrogen; or C,-C3alkyl.
A in formula (1 ) is especially amino; phenyl; or C,-C5alkoxyphenyl.
R3 in formula (1) is especially hydrogen. Special preference is given to compounds of formula (1) wherein R, and R2 are C,-C5alkyl.
Examples of compounds according to the invention are listed in Table 1 below:
Figure imgf000005_0001
Figure imgf000006_0001
Figure imgf000007_0001
Figure imgf000008_0001
Figure imgf000009_0001
Especially preferred are compounds of formulae
Figure imgf000010_0001
and
Figure imgf000010_0002
The triazine derivatives of formula (1) according to the invention are prepared in a manner known perse by reacting a diaminotriazine compound of formula
Figure imgf000010_0003
wherein
R4 is C,-C5alkyl and R„ R2, R3, A and n are as defined for formula (1), to form a compound of formula (1). The reaction is carried out in the presence of an acid, with or without the addition of one or more solvents at a reaction temperature of from 0 to 200°C.
Generally from 0.8 to 2.0 mol of the compound of formula (1 b) and from 0.8 to 2.0 mol of a compound of formula (1 c) are used per free amino group of compound (l a).
The reaction is preferably carried out in DMSO, N-methylpyrroIidone, DMF or DMA. It is also possible, however, to use protic solvents, such as ethanol, methanol, isobutanol or iso- propanol. The reaction can also be carried out in an aliphatic or aromatic solvent, such as hexane, toluene or xylene. It is also possible to use ethers, such as diethyl ether and tetrahy- drofuran, or halogenated solvents, such as chloroform or dichloromethane.
The reaction is preferably carried out as a one-pot reaction. The individual reactants may, however, be added in any desired order. For example, the catalyst may be present from the beginning or may be introduced only later. It is also possible first to start the reaction between (1 b) and (1 c) in the presence of the catalyst and only later to add the triazine compound of formula (1 a). It is equally possible first to react the compound of formula (1 a) with the compound of formula (1 b) in the presence of a catalyst and to add (1 c) later. The reaction can be carried out at a temperature of from 0 to 200°C, preferably at from 20 to 100°C and especially from 50 to 80°C.
The reaction times are dependent upon the reaction temperature. Within the preferred temperature range, the reactions are generally completed within from 1 to 6 hours. At low temperatures, the reaction time increases considerably and may be 48 hours or more.
As catalysts there are used organic and inorganic Brδnstedt or Lewis acids or mixtures thereof. Examples of typical acids are phosphoric acid, trifluoroacetic acid, oxalic acid, methanesulfonic acid, toluenesulfonic acid, phenylsulfonic acid and trifluoromethanesulfonic acid. Also effective are acid anhydrides, for example trifluoromethanesulfonic anhydride, methanesulfonic anhydride and acetic anhydride. Preference is given, however, to the use of Lewis acids, such as phosphorus oxychloride, copper chlorides, zinc chloride, lanthanum chloride, chromium chlorides, iron chlorides, aluminium chloride, titanium chlorides, germanium chloride, and hydrates thereof. It is also possible to use acidic ion exchangers.
The product is isolated according to conventional techniques, such as filtration, centrifuga- tion, phase separation and liquid extraction. The products are purified, inter alia, by recrys- tallisation from a solvent or from a solvent mixture, preference being given to solvents or solvent mixtures containing alcohols. Purification can also be carried out by chroma- tographic methods and by distillation.
The compounds of formula (1) according to the invention are suitable especially as UV filters, that is to say to protect organic materials that are sensitive to ultraviolet light, especially human and animal skin and hair, against the damaging effect of UV radiation. The compounds are accordingly suitable as light-protective agents in cosmetic, pharmaceutical and veterinary medicine preparations. The compounds can be used either in the dissolved state or in the micronised state.
The invention accordingly relates also to a cosmetic preparation comprising at least one compound of formula (1 ), and to cosmetically tolerable carriers or adjuvants.
In addition to the UV absorber according to the invention, the cosmetic preparation may also comprise one or more further UV protective substances of the following substance classes:
1. p-aminobenzoic acid derivatives, for example 4-dimethylaminobenzoic acid 2- ethylhexyl ester;
2. salicylic acid derivatives, for example salicylic acid 2-ethylhexyl ester;
3. benzophenone derivatives, for example 2-hydroxy-4-methoxybenzophenone and its 5-sulfonic acid derivative;
4. dibenzoylmethane derivatives, for example 1 -(4-tert-butylphenyl)-3-(4-methoxyphenyl)- propane-1 ,3-dione; 5. diphenylacrylates, for example 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, and 3- (benzofuranyl) 2-cyanoacrylate;
6. 3-imidazol-4-ylacrylic acid and esters;
7. benzofuran derivatives, especially 2-(p-aminophenyl)benzofuran derivatives, described in EP-A-582 189, US-A-5 338 539, US-A-5 518 713 and EP-A-61 3 893;
8. polymeric UV absorbers, for example the benzylidene malonate derivatives described in EP-A-709 080;
9. cinnamic acid derivatives, for example the 4-methoxycinnamic acid 2-ethylhexyl ester and isoamyl ester or cinnamic acid derivatives disclosed in US-A-5 601 81 1 and
WO 97/00851;
10. camphor derivatives, for example 3-(4'-methyl)benzylidene-boman-2-one, 3-benzyl- ideneboman-2-one, N-[2(and 4)-2-oxyborn-3-ylidene-methyl)-benzyl]acrylamide polymer, 3-(4'-trimethylammonium)-benzylidene-bornan-2-one methyl sulfate, 3,3'-(1 ,4- phenylenedimethine)-bis(7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptane-1 -methanesulfonic acid) and salts, 3-(4'-sulfo)benzylidene-boman-2-one and salts; camphorbenzalkonium methosulfate;
1 1. hydroxyphenyltriazine compounds, for example 2-(4'-methoxyphenyl)-4,6-bis(2'- hydroxy-4'-n-octyloxyphenyl)-1,3,5-triazine; 2,4-bis{[4-(3-(2-propyloxy)-2-hydroxy- propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1 ,3,5-triazine; 2,4-bis{[4-(2-ethyl- hexyloxy)-2-hydroxyJ-phenyl}-6-[4-(2-methoxyethyl-carboxyl)-phenylamino]-1 ,3,5- triazine; 2,4-bis{[4-(tris(trimethylsilyloxy-silylpropyloxy)-2-hydroxy]-phenyl}-6-(4- methoxyphenyl)-1 ,3,5-triazine; 2,4-bis{[4-(2"-methylpropenyloxy)-2-hydroxy]-phenyl}- 6-(4-methoxyphenyl)-1 ,3,5-triazine; 2,4-bis{[4-(1 ',1 ',1 ',3',5',5',5'-heptamethyltrisilyl-2"- methyl-propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine; 2,4-bis{[4- (3-(2-propyloxy)-2-hydroxy-propyloxy)-2-hydroxy]-phenyl}-6-[4-ethylcarboxy)- phenylamino]-1 ,3,5-triazine; 12. benzotriazole compounds, for example 2,2'-methylene-bis(6-(2H-benzotriazol-2-yl)-4-
(1 ,1 ,3,3-tetramethylbutyl)-phenol
Figure imgf000014_0001
1 3. trianilino-s-triazine derivatives, for example 2,4,6-trianiline-(p-carbo-2'-ethyl-1 '-oxy)- 1,3,5-triazine and the UV absorbers disclosed in US-A-5 332 568, EP-A-517 104, EP-A-507 691 , WO 93/17002 and EP-A-570 838;
14. 2-phenylbenzimidazole-5-sulfonic acid and salts thereof;
15. menthyl o-aminobenzoate;
16. TiO2 (variously encapsulated), ZnO and mica.
The UV absorbers described in "Sunscreens", Eds. N.j. Lowe, N.A.Shaath, Marcel Dekker, Inc. , New York and Basle or in Cosmetics & Toiletries (107), 50ff (1992) also can be used as additional UV protective substances.
Special preference is given to the light-protective agents indicated in the following Table:
INCi Chemical Name CAS No.
3-BENZYLIDENE CAMPHOR 1 ,7,7-trimethyl-3-(phenylmethylene 15087-24-8 bicyclo[2.2.1]heptan-2-one
4-METHYLBENZYUDENE (+/-)-1 ,7,7-trimethyl-3-[(4-methylphenyl)- 36861 -47-9 CAMPHOR methylene]bicyclo[2.2.1]heptan-2-one
BENZOPHENONE-10 (2-hydroxy-4-methoxyphenyl)-(4-methyl- 1641 -17-4 phenyl)methanone
BENZOPHENONE-1 2,4-dihydroxybenzophenone 131 -56-6
BENZOPHENONE-2 2,2',4,4'-tetrahydroxybenzophenone 131 -55-5
BENZOPHENONE-3 2-hydroxy-4-methoxybenzophenone; 131 -57-7 INCI Chemical Name CAS No.
BENZOPHENONE-4 2-hydroxy-4-methoxybenzophenone-5- 4065-45-6 sulfonic acid
BENZOPHENONE-6 2,2'-dihydroxy-4,4'-dimethoxybenzophenone 131 -54-4
BENZOPHENONE-8 2,2'-dihydroxy-4-methoxybenzophenone 131-53-3
BENZYLIDENE CAMPHOR alpha-(2-oxoborn-3-ylidene)-toluene-4-sul- 56039-58-8 SULFONIC ACID fonic acid and its salts
BUTYL METHOXY- 1 -[4-(1 ,1 -dimethylethyl)phenyl]-3-(4- 70356-09-1 DIBENZOYLMETHANE methoxyphenyl)propane-1 ,3-dione
CAMPHOR BENZALKONIUM methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3- 52793-97-2 METHOSULFATE oxobicyclo[2,2,1 ]hept-2-ylidene)- methyϊjanilinium sulfate
CINOXATE 2-ethoxyethyl p-methoxycinnamate 104-28-9
DEA-METHOXYCINNAMATE diethanolamine salt of p-methoxy- 56265-46-4 hydrocinnamate
DIISOPROPYL METHYL 2-propenoic acid, 3-[2,4-bis(1- 32580-71-5 CINNAMATE methylethyl)phenyl]-, methyl ester
DIPROPYLENE GLYCOL dipropylene glycol salicylate 7491 -14-7 SAUCYLATE
ETHYL DIHYDROXYPROPYL ethyl 4-bis(2-hydroxypropyl)-amino-benzoate 58882-1 7-0 PABA
ETHYL DIISOPROPYLCIN- ethyl 3- [2,4-bis(1 -methylethyl)phenyl]- 32580-72-6 NAMATE acrylate
ETHYL METHOXY- ethyl p-methoxycinnamate 1929-30-2 CINNAMATE
GLYCERYL OCTANOATE
DIMETHOXYCINNAMATE
GLYCERYl PABA glyceryl 1 -(4-aminobenzoate) 136-44-7
HOMOSALATE 3,3,5-trimethylcyclohexyl-2-hydroxy-benzoate1 18-56-9 INCI Chemical Name CAS No.
ISOAMYL p-METHOXY- isopentyl p-methoxycinnamate 71617-10-2 CINNAMATE
ISOPROPYL DIBENZOYL1 -[4-(1 -methylethyl)phenyl]-3-phenyl- 63250-25-9 METHANE propane-1,3-dione
ISOPROPYL METHOXY- isopropyl p-methoxycinnamate 5466-76-2 CINNAMATE
LAWSONE 2-hydroxy-1 ,4-naphthoquinone 83-72-7
MENTHYL ANTHRANILATE menthyl o-aminobenzoate 134-09-8
MENTHYL SALICYLATE menthyl salicylate 89-46-3
OCTOCRYLENE 2-ethylhexyl 2-cyano-3,3-diphenyl acrylate 6197-30-4
ETHYLHEXYL DIMETHYL PABA 2-ethylhexyl 4-(dimethylamino)benzoate 21245-02-3
ETHYLHEXYL METHOXY- 2-ethylhexyl 4-methoxycinnamate 5466-77-3 CINNAMATE
ETHYLHEXYL SALICYLATE 2-ethylhexyl salicylate 118-60-5
ETHYLHEXYL TRIAZONE benzoic acid, 4,4',4"-(1,3,5-triazine-2,4,6- 88122-99-0 triyltriimino)tris-, tris(2-ethylhexyl) ester; 2,4,6-trianilino-(p-carbo-2'-ethylhexyl-1 '-oxy)- 1 ,3,5-triazine
PABA 4-aminobenzoic acid 150-1 3-0
PEG-25 PABA benzoic acid, 4-amino-, ethyl ester, 113010-52-9 polymer with oxirane
PENTYL DIMETHYL PABA amyl dimethyl PABA 14779-78-3
PHENYLBENZIMIDAZOLE 2-phenyl-1 H-benzimidazole-5-sulfonic 27503-81-7 SULFONIC ACID acid
POLYACRYLAMIDOMETHYL 113783-61 -2 BENZYLIDENE CAMPHOR
TEA-SALICYLATE triethanolamine salicylate 2174-16-5 INCI Chemical Name CAS No.
TEREPHTHALYUDENE Dl- 3,3'-(1 ,4-phenylenedimethylene)bis[7,7- 90457-82-2 CAMPHOR SULFONIC ACID dimethyl-2-oxo-bicyclo[2.2.1 ]heptane-1 - methanesulfonic acid]
TITANIUM DIOXIDE titanium dioxide 13463-67-7
DIGALLOYL TRIOLEATE digalloyl trioleate 17048-39-4
ZINC OXIDE zinc oxide 1314-13-2
Methylene bis-benzotriazolyl 2,2'-methylene-bis[6-(2H-benzotriazol-2-yl)-4- 103597-45-1 tetramethylbutylphenol (1 ,1 ,3,3-tetramethylbutyl)-phenol]
Bis-ethylhexyloxyphenol 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]- 187393-00-6 methoxyphenyltriazine phenyl}-6-(4-methoxyphenyl)-(1 ,3,5)-triazine
BISIMIDAZYLATE 1 H-benzimidazole-4,6-disulfonic acid, 180898-37-7
2,2'-(1,4-phenylene)bis-, disodium salt
DIETHYLHEXYL BUTAMIDO benzoic acid, 4,4'-[[6-[[4-[[(1,1 -dimethyl- 154702-15-5 TRIAZONE ethyl)amino]carbonyl]phenyl]amino]-1 ,3,5- triazine-2,4-diyl]diimino]bis-, bis(2-ethyl- hexyl) ester
DROMETRIZOLE TRISI- phenol, 2-(2H-benzotriazol-2-yl)-4-methyl-6- 155633-54-8 LOXANE [2-methyl-3-[1 ,3,3,3-tetramethyl-1 -[(tri- methylsilyl)oxy]disiloxanyl]propyl]-
BENZYLIDENE MALONATE alpha-(trimethylsilyl)-omega-(trimethyl-silyl- 207574-74-1 POLYSILOXANE oxy)poly[oxy(dimethyl)silylene]-co-[oxy-
(methyl)(2-{p-[2,2-bis(ethoxycarbonyl)vinyl]- phenoxy}-1 -methyleneethyl)silylene]-co-[oxy-
(methyl)(2-{p-[2,2-bis(ethoxycarbonyl)vinyl]- phenoxy}prop-1 -enyl)silylene]
2-(4-diethylamino-2-hydroxybenzoyl)-benzoic 302776-68-7 hexyl ester
Each of the above-mentioned light-protective agents, especially the light-protective agents in Table 1 indicated as being preferred, can be used in admixture with the UV absorbers according to the invention. It will be understood in that connection that, in addition to the UV absorbers according to the invention, it is also possible for more than one of the additional light-protective agents to be used, for example, two, three, four, five or six further light- protective agents.
Preference is given to the use of mixing ratios of UV absorbers according to the invention/further light-protective agents of from 1 :99 to 99:1, especially from 1 :95 to 95:1 and preferably from 10:90 to 90:10, based on weight. Of special interest are mixing ratios of from 20:80 to 80:20, especially from 40:60 to 60:40 and preferably of approximately 50:50. Such mixtures can be used, inter alia, to improve solubility or increase UV absorption.
Appropriate mixtures can be used especially advantageously in the cosmetic preparations described below.
The cosmetic preparations are suitable especially as UV filters, that is to say for the protection of organic materials that are sensitive to ultraviolet light, especially skin and hair, against the damaging effect of UV radiation.
The UV absorbers can be used either in the dissolved state or in the micronised state.
Any known process suitable for the preparation of microparticles can be used for the preparation of the micronised UV absorbers, for example:
- wet-grinding with a hard grinding medium, for example zirconium silicate and a protective surfactant or a protective polymer in water or in a suitable organic solvent;
- spray-drying from a suitable solvent, for example aqueous suspensions or suspensions containing organic solvents, or true solutions in water, ethanol, dichloroethane, toluene, N-methylpyrrolidone inter alia;
- by the expansion according to the RESS process (Rapid Expansion of Supercritical Solutions) of supercritical fluids (e.g. C02) in which the UV filter or filters is/are dissolved or the expansion of fluid carbon dioxide together with a solution of one or more UV filters in a suitable organic solvent; - by reprecipitation from suitable solvents, including supercritical fluids (GASR process = Gas Anti-Solvent Recrystallisation / PCA process = Precipitation with Compressed Antisol- vents).
As grinding apparatus for the preparation of the micronised organic UV absorbers there may be used, for example, a jet mill, ball mill, vibratory mill or hammer mill, preferably a highspeed mixing mill. The grinding is preferably carried out with a grinding aid, for example an alkylated vinylpyrrolidone polymer, a vinylpyrrolidone/vinyl acetate copolymer, an acyl glu- tamate, an alkyl polyglucoside, ceteareth-25 or a phospholipid.
The micronised UV absorbers so obtained usually have an average particle size that is from 0.02 to 2, preferably from 0.05 to 1.5, and more especially from 0.1 to 1.0, nm.
The UV absorbers can also be used dry in powder form. For that purpose the UV absorbers are subjected to known grinding methods, such as vacuum atomization, countercurrent spray-drying etc.. Such powders have a particle size of from 0.1 nm to 2 μm. To avoid the occurrence of agglomeration, the UV absorbers can be coated with a surface-active compound prior to the pulverisation process, for example with an anionic, non-ionic or ampho- teric surfactant, e.g. a phospholipid or a known polymer, such as PVP, an acrylate etc..
The cosmetic preparations contain, for example, from 0.1 to 30 % by weight, preferably from 0.1 to 15 % by weight and especially from 0.5 to 10 % by weight, based on the total weight of the composition, of one or more UV absorbers and at least one cosmetically tolerable adjuvant.
The cosmetic preparations can be prepared by physically mixing the UV absorber(s) with the adjuvant using customary methods, for example by simply stirring together the individual components, especially by making use of the dissolution properties of already known cosmetic UV absorbers, for example OMC, salicylic acid isooctyl ester, inter alia. The UV absorber can be used, for example, without further treatment, or in the micronised state, or in the form of a powder. The cosmetic preparations may be, for example, creams, gels, lotions, alcoholic and aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders or ointments.
As water- and oil-containing emulsions (e.g. W/O, O/W, O/W/O and W/O/W emulsions or microemulsions) the preparations contain, for example, from 0.1 to 30 % by weight, preferably from 0.1 to 15 % by weight and especially from 0.5 to 10 % by weight, based on the total weight of the composition, of one or more UV absorbers, from 1 to 60 % by weight, especially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition, of at least one oil component, from 0 to 30 % by weight, especially from 1 to 30 % by weight und preferably from 4 to 20 % by weight, based on the total weight of the composition, of at least one emulsifier, from 10 to 90 % by weight, especially from 30 to 90 % by weight, based on the total weight of the composition, of water, and from 0 to 88.9 % by weight, especially from 1 to 50 % by weight, of further cosmetically tolerable adjuvants.
As oil components of oil-containing compositions (e.g. oils, W/O, O/W, O/W/O and W/O/W emulsions or microemulsions) there come into consideration, for example, Guerbet alcohols based on fatty alcohols having from 6 to 18, preferably from 8 to 10, carbon atoms, esters of linear C6-C24 fatty acids with linear C3-C24 alcohols, esters of branched C6-C13carboxylic acids with linear C6-C24 fatty alcohols, esters of linear C6-C24 fatty acids with branched alcohols, especially 2-ethylhexanol, esters of hydroxycarboxylic acids with linear or branched C6-C22 fatty alcohols, especially dioctyl malates, esters of linear and/or branched fatty acids with polyhydric alcohols (for example propylene glycol, dimer diol or trimer triol) and/or Guerbet alcohols, triglycerides based on C6-C10 fatty acids, liquid mono-/di-/tri-glyceride mixtures based on C6-C,8 fatty acids, esters of C6-C24 fatty alcohols and/or Guerbet alcohols with aromatic carboxylic acids, especially benzoic acid, esters of C2-C12dicarboxylic acids with linear or branched alcohols having from 1 to 22 carbon atoms or polyols having from 2 to 10 carbon atoms and from 2 to 6 hydroxy groups, vegetable oils (such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheatgerm oil, peach kernel oil and the liquid components of coconut oil), branched primary alcohols, substituted cyclo- hexanes, linear and branched C6-C22 fatty alcohol carbonates, Guerbet carbonates, esters of benzoic acid with linear and/or branched C6-C22alcohols (e.g. Finsolv® TN), linear or branched, symmetric or asymmetric dialkyl ethers having a total of from 12 to 36 carbon atoms, especially from 12 to 24 carbon atoms, for example di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di-n-undecyl ether, di-n-dodecyl ether, n-hexyl n-octyl ether, n-octyl n- decyl ether, n-decyl n-undecyl ether, n-undecyl n-dodecyl ether, n-hexyl n-undecyl ether, di-tert-butyl ether, diisopentyl ether, di-3-ethyldecyI ether, tert-butyl n-octyl ether, isopentyl n-octyl ether and 2-methyl pentyl-n-octyl ether; ring-opening products of epoxidised fatty acid esters with polyols, silicone oils and/or aliphatic or naphthenic hydrocarbons. Also of importance are monoesters of fatty acids with alcohols having from 3 to 24 carbon atoms. That group of substances comprises the esterification products of fatty acids having from 8 to 24 carbon atoms, for example caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and technical- grade mixtures thereof (obtained, for example, in the pressure removal of natural fats and oils, in the reduction of aldehydes from Roelen's oxosynthesis or in the dimerisation of un- saturated fatty acids) with alcohols, for example, isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linoyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachidyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and technical-grade mixtures thereof (obtained, for example, in the high-pressure hydrogenation of technical-grade methyl esters based on fats and oils or aldehydes from Roelen's oxosynthesis and as monomer fractions in the dimerisation of unsaturated fatty alcohols). Of special importance are isopropyl myristate, isononanoic acid Cl6-C18alkyl esters, stearic acid 2- ethylhexyl ester, cetyl oleate, glycerol tricaprylate, coconut fatty alcohol caprinate/caprylate and n-butyl stearate. Further oil components that can be used are dicarboxylic acid esters, such as di-n-butyl adipate, di(2-ethylhexyl) adipate, di(2-ethylhexyl) succinate and diiso- tridecyl acetate, and also diol esters, such as ethylene glycol dioleate, ethylene glycol diiso- tridecanoate, propylene glycol di(2-ethylhexanoate), propylene glycol diisostearate, propylene glycol dipelargonate, butanediol diisostearate and neopentyl glycol dicaprylate. Preferred mono- or poly-ols are ethanol, isopropanol, propylene glycol, hexylene glycol, glycerol and sorbitol. It is also possible to use di- and/or tri-valent metal salts (alkaline earth metal, Al3+ inter alia) of one or more alkylcarboxylic acids.
The oil components can be used in an amount of, for example, from 1 to 60 % by weight, especially from 5 to 50 % by weight and preferably from 10 to 35 % by weight, based on the total weight of the composition.
Any conventionally usable emulsifier can be used for the compositions.
As emulsifiers there come into consideration, for example, non-ionic surfactants from the following groups:
- addition products of from 2 to 30 mol of ethylene oxide and/or from 0 to 5 mol of propylene oxide with linear fatty alcohols having from 8 to 22 carbon atoms, with fatty acids having from 12 to 22 carbon atoms and with alkylphenols having from 8 to 15 carbon atoms in the alkyl group, for example ceteareth-20 or ceteareth-12;
- C,2-C22 fatty acid mono- and di-esters of addition products of from 1 to 30 mol of ethylene oxide with polyols having from 3 to 6 carbon atoms, especially with glycerol;
- glycerol mono- and di-esters and sorbitan mono- and di-esters of saturated and unsatu- rated fatty acids having from 6 to 22 carbon atoms and ethylene oxide addition products thereof, for example glyceryl stearates, glyceryl isostearates, glyceryl oleates, sorbitan oleates or sorbitan sesquioleates;
- C8-C22alkyl-mono- and -oligo-glycosides and ethoxylated analogues thereof, degrees of oligomerisation of from 1.1 to 5, especially from 1 .2 to 1 .4, being preferred, and glucose being preferred as the sugar component; - addition products of from 2 to 60 mol, especially from 15 to 60 mol, of ethylene oxide with castor oil and/or hardened castor oil;
- polyol esters and especially polyglycerol esters, for example diisostearoyl polyglyceryl-3- diisostearates, polyglyceryl-3-diisostearates, triglyceryl diisostearates, polyglyceryl-2- sesquiisostearates or polyglyceryl dimerates. Mixtures of compounds from a plurality of those substance classes are also suitable;
- partial esters based on linear, branched, unsaturated or saturated C6-C22 fatty acids, rici- noleic acid and also 12-hydroxystearic acid and on glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and also polyglucosides (e.g. cellulose), for example po- lyglyceryl-2-dihydroxystea rates or polygIyceryl-2-diricinoIeates;
- mono-, di- and tri-alkylphosphates and also mono-, di- and/or tri-PEG-alkylphosphates and salts thereof;
- wool wax alcohols;
- one or more ethoxylated esters of natural derivatives, for example polyethoxylated esters of hydrogenated castor oil;
- silicone oil emulsifiers, for example silicone polyol;
- polysiloxane/polyalkyl/polyether copolymers and corresponding derivatives, for example cetyl dimethicone copolyol;
- mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol (see
DE-A-1 1 65 574) and/or mixed esters of fatty acids having from 6 to 22 carbon atoms, methylglucose and polyols, preferably glycerol or polyglycerol, for example polyglyceryl- 3-glucose distearates, polyglyceryl-3-glucose dioleates, methyl glucose dioleates or dico- coyl pentaerythryl distearyl citrates and also
- polyalkylene glycols.
The addition products of ethylene oxide and/or of propylene oxide with fatty alcohols, fatty acids, alkylphenols, glycerol mono- and di-esters and also sorbitan mono- and di-esters of fatty acids, or with castor oil, are known, commercially available products. They are usually homologue mixtures, the average degree of alkoxylation of which corresponds to the ratio of the amounts of ethylene oxide and/or propylene oxide and substrate with which the ad- dition reaction is carried out. C,2-C,s fatty acid mono- and di-esters of addition products of ethylene oxide with glycerol are known, for example, from DE-A-2 024 051 as fat-restoring substances for cosmetic preparations.
C8-C18Alkyl-mono- and -oligo-glycosides, their preparation and their use are known from the prior art. They are prepared especially by reacting glucose or oligosaccharides with primary alcohols having from 8 to 18 carbon atoms. Suitable glycoside radicals include mono- glycosides in which a cyclic sugar radical is glycosidically bonded to the fatty alcohol and also oligomeric glycosides having a degree of oligomerisation of up to preferably about 8. The degree of oligomerisation is a statistical average value based on a homologue distribution customary for such technical-grade products.
It is also possible to use zwitterionic surfactants as emulsifiers. The term "zwitterionic surfactants" denotes especially surface-active compounds that carry at least one quaternary ammonium group and at least one carboxylate and/or sulfonate group in the molecule. Zwitterionic surfactants that are especially suitable are the so-called betaines, such as N-alkyl- N,N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N,N-dimethylammonium glycinates, for example cocoacylaminopropyl- dimethylammonium glycinate, and 2-a!kyl-3-carboxymethyl-3-hydroxyethylimidazolines each having from 8 to 18 carbon atoms in the alkyl or acyl group and also cocoacylamino- ethylhydroxyethylcarboxymethylglycinate. Special preference is given to the fatty acid amide derivative known by the CTFA name cocamidopropyl betaine. Likewise suitable as emulsifiers are ampholytic surfactants. Ampholytic surfactants are to be understood as meaning especially those which, in addition to containing a C8-C18-alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -S03H group in the molecule and are capable of forming internal salts. Examples of suitable ampholytic surfactants include N- alkylglycines, N-alkylpropionic acids, N-aikylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids, each having approximately from 8 to 18 carbon atoms in the alkyl group. Ampholytic surfactants to which special preference is given are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C12-C,8- acylsarcosine. In addition to the ampholytic emulsifiers there also come into consideration quaternary emulsifiers, special preference being given to those of the esterquat type, preferably methyl-quaternised di-fatty acid triethanolamine ester salts.
Non-ionic emulsifiers are preferred. Of the non-ionic emulsifiers mentioned, special preference is given to ethoxylated fatty alcohols having from 8 to 22 carbon atoms and from 4 to 30 EO units.
The emulsifiers may be used in an amount of, for example, from 1 to 30 % by weight, especially from 4 to 20 % by weight and preferably from 5 to 10 % by weight, based on the total weight of the composition. It is, however, also possible in principle to dispense with the use of emulsifiers.
The preparations according to the invention, for example creams, gels, lotions, alcoholic and aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders or ointments, may in addition contain, as further adjuvants and additives, mild surfactants, super-fatting agents, pearlescent waxes, consistency regulators, thickeners, polymers, silicone compounds, fats, waxes, stabilisers, biogenic active ingredients, deodorising active ingredients, anti-dandruff agents, film formers, swelling agents, further UV light-protective factors, antioxidants, hydrotropic agents, preservatives, insect repellents, self-tanning agents, solubilisers, perfume oils, colourants, bacteria-inhibiting agents and the like.
Substances suitable for use as super-fatting agents are, for example, lanolin and lecithin and also polyethoxylated or acrylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides, the latter simultaneously acting as foam stabilisers.
Examples of suitable mild surfactants, that is to say surfactants especially well tolerated by the skin, include fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, mono- and/or di-alkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides, fatty acid glutamates, α-olefin sulfonates, ether carboxylic acids, alkyl oligogluco- sides, fatty acid glucamides, alkylamidobetaines and/or protein fatty acid condensation products, the latter preferably being based on wheat proteins.
As pearlescent waxes there come into consideration, for example: alkylene glycol esters, especially ethylene glycol distearate; fatty acid alkanolamides, especially coco fatty acid di- ethanolamide; partial glycerides, especially stearic acid monoglyceride; esters of polyvalent, unsubstituted or hydroxy-substituted carboxylic acids with fatty alcohols having from 6 to 22 carbon atoms, especially long-chained esters of tartaric acid; fatty substances, for example fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which in total have at least 24 carbon atoms, especially laurone and distearyl ether; fatty acids, such as stearic acid, hydroxystearic acid or behenic acid, ring-opening products of olefin epoxides having from 12 to 22 carbon atoms with fatty alcohols having from 12 to 22 carbon atoms and/or polyols having from 2 to 15 carbon atoms and from 2 to 10 hydroxy groups, and mixtures thereof.
As consistency regulators there come into consideration especially fatty alcohols or hydroxy fatty alcohols having from 12 to 22 carbon atoms and preferably from 16 to 18 carbon atoms, and in addition partial glycerides, fatty acids and hydroxy fatty acids. Preference is given to a combination of such substances with alkyl-oligoglucosides and/or fatty acid N-methylglucamides of identical chain length and/or polyglycerol poly-12-hydroxystearates. Suitable thickeners include, for example, Aerosil types (hydrophilic silicic acids), polysaccha- rides, especially xanthan gum, guar-guar, agar-agar, alginates and Tyloses, carboxymethyl cellulose and hydroxymethyl cellulose, also relatively high molecular weight polyethylene glycol mono- and di-esters of fatty acids, polyacrylates (e.g. Carbopol® from Goodrich or Synthalen® from Sigma), polyacrylamides, polyvinyl alcohol and polyvinylpyrrolidone, surfactants, for example ethoxylated fatty acid glycerides, esters of fatty acids with polyols, for example pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with restricted homologue distribution and alkyl-oligoglucosides as well as electrolytes, such as sodium chloride or ammonium chloride. Suitable cationic polymers are, for example, cationic cellulose derivatives, for example a qua- temised hydroxymethyl cellulose obtainable under the name Polymer JR 400® from Amer- chol, cationic starch, copolymers of diallylammonium salts and acrylamides, quaternised vi- nylpyrrolidone/vinyl imidazole polymers, for example Luviquat® (BASF), condensation products of polyglycols and amines, quaternised collagen polypeptides, for example lauryldimo- nium hydroxypropyl hydrolyzed collagen (Lamequat®L/Grϋnau), quaternised wheat polypeptides, polyethyleneimine, cationic silicone polymers, for example amidomethicones, co- polymers of adipic acid and dimethylaminohydroxypropyldiethylenetriamine (Car- taretin®/Sandoz), copolymers of acrylic acid with dimethyldiallylammonium chloride (Mer- quat® 550/Chemviron), polyaminopolyamides, as described, for example, in FR-A-2 252 840, and the crosslinked water-soluble polymers thereof, cationic chitin derivatives, for example of quaternised chitosan, optionally distributed as microcrystals; condensation products of dihaloalkyls, for example dibromobutane, with bisdialkylamines, for example bisdi- methylamino-1 ,3-propane, cationic guar gum, for example Jaguar® C-17, Jaguar® C-16 from Celanese, quaternised ammonium salt polymers, for example Mirapol® A-15, Mirapol® AD-1, Mirapol® AZ-1 from Miranol.
As anionic, zwitterionic, amphoteric and non-ionic polymers there come into consideration, for example, vinyl acetate/crotonic acid copolymers, vinylpyrrolidone/vinyl acrylate copolymers, vinyl acetate/butyl maleate/isobomyl acrylate copolymers, methyl vinyl ether/maleic anhydride copolymers and esters thereof, uncrosslinked polyacrylic acids and polyacrylic acids crosslinked with polyols, acrylamidopropyltrimethylammonium chloride/acrylate copolymers, octyl acrylamide/methyl methacrylate/tert-butylaminoethyl methacrylate/2- hydroxypropyl methacrylate copolymers, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, vinylpyrrolidone/dimethylaminoethyl methacrylate/vinyl caprolactam ter- polymers and also optionally derivatised cellulose ethers and silicones.
Suitable silicone compounds are, for example, dimethylpolysiloxanes, methylphenyl- polysiloxanes, cyclic silicones, and also amino-, fatty acid-, alcohol-, polyether-, epoxy-, fluorine-, glycoside- and/or alkyl-modified silicone compounds, which at room temperature may be in either liquid or resinous form. Also suitable are simethicones, which are mixtures of dimethicones having an average chain length of from 200 to 300 dimethylsiloxane units with hydrogenated silicates. A detailed survey by Todd et al. of suitable volatile silicones may in addition be found in Cosm. Toil. 91 , 27 (1976).
Typical examples of fats are glycerides, and as waxes there come into consideration, inter alia, beeswax, camauba wax, candelilla wax, montan wax, paraffin wax, hydrogenated castor oils and fatty acid esters or microwaxes solid at room temperature optionally in combination with hydrophilic waxes, e.g. cetylstearyl alcohol or partial glycerides. Metal salts of fatty acids, for example magnesium, aluminium and/or zinc stearate or ricinoleate, may be used as stabilisers.
Biogenic active ingredients are to be understood as meaning, for example, tocopherol, to- copherol acetate, tocopherol palmitate, ascorbic acid, deoxyribonucleic acid, retinol, bis- abolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudocera- mides, essential oils, plant extracts and vitamin complexes.
As deodorising active ingredients there come into consideration, for example, anti- perspirants, for example aluminium chloro hydrates (see J. Soc. Cosm. Chem. 24, 281 (1973)). Under the trade mark Locron® of Hoechst AG, Frankfurt (FRG), there is available commercially, for example, an aluminium chlorohydrate corresponding to formula AI2(OH)5CI x 2.5 H20, the use of which is especially preferred (see J. Pharm. Pharmacol. 26, 531 (1975)). Besides the chlorohydrates, it is also possible to use aluminium hydroxy- acetates and acidic aluminium/zirconium salts. Esterase inhibitors may be added as further deodorising active ingredients. Such inhibitors are preferably trialkyl citrates, such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate and especially triethyl citrate (Hydagen® CAT, Henkel KGaA, Dϋsseldorf/FRG), which inhibit enzyme activity and hence reduce odour formation. Further substances that come into consideration as esterase inhibitors are sterol sulfates or phosphates, for example lanosterol, cholesterol, campesterol, stigmasterol and sitosterol sulfate or phosphate, dicarboxylic acids and esters thereof, for example glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid and malonic acid diethyl ester and hydroxycarboxylic acids and esters thereof, for example citric acid, malic acid, tar- taric acid or tartaric acid diethyl ester. Antibacterial active ingredients that influence the mi- crobial flora and kill or inhibit the growth of sweat-decomposing bacteria can likewise be present in the preparations (especially in stick preparations). Examples include chitosan, phenoxyethanol and chlorhexidine gluconate. 5-Chloro-2-(2,4-dichlorophenoxy)-phenol (Ir- gasan®, Ciba Specialty Chemicals Inc.) has also proved especially effective.
As anti-dandruff agents there may be used, for example, climbazole, octopirox and zinc py- rithione. Customary film formers include, for example, chitosan, microcrystalline chitosan, quaternised chitosan, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, polymers of quaternary cellulose derivatives containing a high proportion of acrylic acid, collagen, hyaluronic acid and salts thereof and similar compounds. As swelling agents for aqueous phases there may be used montmorillonites, clay mineral substances, Pemulen and also alkyl-modified types of Carbopol (Goodrich). Further suitable polymers and swelling agents can be found in the review by R. Lochhead in Cosm. Toil. 108, 95 (1993).
In addition to the primary light-protective substances it is also possible to use secondary light-protective substances of the antioxidant kind which interrupt the photochemical reaction chain triggered when UV radiation penetrates the skin or hair. Typical examples of such antioxidants are amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides, such as D,L- carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotinoids, carotenes (e.g. cc-carotene, β-carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothiogly- cose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cys- tamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl, lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters thereof) and also salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and also sulfoximine compounds (e.g. buthionine sulfoximines, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, hepta-thionine sulfoximine) in very small tolerable amounts (e.g. from pmol to μmol/kg), also (metal) chelating agents (e.g. α-hydroxy fatty acids, palmitic acid phytic acid, lactofer- rin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof (e.g. γ-linolenic acid, linoleic acid, oleic acid), folic acid and derivatives thereof, ubiquinone and ubiquinol and derivatives thereof, vitamin C and derivatives (e.g. ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (e.g. vitamin A palmitate) and also coniferyl benzoate of benzoin resin, rutinic acid and derivatives thereof, α-glycosylrutin, ferulic acid, furfurylidene glucitol, camosine, butyl hydroxytoluene, butyl hydroxyanisole, resinous nordihydroguaiaretic acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, superoxide dismutase, N- [3-(3,5-di-tert-butyI-4-hydroxyphenyl)propionyl]sulfaniIic acid (and salts thereof, for example the disodium salts), zinc and derivatives thereof (e.g. ZnO, ZnSO , selenium and derivatives thereof (e.g. selenium methionine), stilbene and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of those mentioned active ingredients. HALS (="Hindered Amine Light Stabilizers") compounds may also be mentioned. The amount of antioxidants present is usually from 0.001 to 30 % by weight, preferably from 0.01 to 3 % by weight, based on the weight of the UV absorber(s).
To improve the flow behaviour it is also possible to employ hydrotropic agents, for example ethanol, isopropyl alcohol or polyols. The polyols that come into consideration for that purpose have preferably from 2 to 15 carbon atoms and at least two hydroxy groups.
The polyols may also contain further functional groups, especially amino groups, and/or may be modified with nitrogen. Typical examples are as follows:
- glycerol;
- alkylene glycols, for example ethylene glycol, diethylene glycol, propylene glycol, buty- lene glycol, hexylene glycol and also polyethylene glycols having an average molecular weight of from 100 to 1000 dalton; - technical oligoglycerol mixtures having an intrinsic degree of condensation of from 1 .5 to 10, for example technical diglycerol mixtures having a diglycerol content of from 40 to 50 % by weight;
- methylol compounds, such as, especially, trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol and dipentaerythritol;
- lower alkyl-glucosides, especially those having from 1 to 8 carbon atoms in the alkyl radical, for example methyl and butyl glucoside;
- sugar alcohols having from 5 to 12 carbon atoms, for example sorbitol or mannitol;
- sugars having from 5 to 12 carbon atoms, for example glucose or saccharose;
- amino sugars, for example glucamine;
- dialcohol amines, such as diethanolamine or 2-amino-1 ,3-propanediol.
Suitable preservatives include, for example, phenoxyethanol, formaldehyde solution, Para- bens, pentanediol or sorbic acid and the further substance classes listed in Schedule 6, Parts A and B of the Cosmetics Regulations.
There may be mentioned as perfume oils mixtures of natural and/or synthetic aromatic substances. Natural aromatic substances are, for example, extracts from blossom (lilies, lavender, roses, jasmine, neroli, ylang-ylang), from stems and leaves (geranium, patchouli, petit- grain), from fruit (aniseed, coriander, carraway, juniper), from fruit peel (bergamot, lemons, oranges), from roots (mace, angelica, celery, cardamom, costus, iris, calmus), from wood (pinewood, sandalwood, guaiacum wood, cedarwood, rosewood), from herbs and grasses (tarragon, lemon grass, sage, thyme), from needles and twigs (spruce, pine, Scots pine, mountain pine), from resins and balsams (galbanum, elemi, benzoin, myrrh, olibanum, opoponax). Animal raw materials also come into consideration, for example civet and cas- toreum. Typical synthetic aromatic substances are, for example, products of the ester, ether, aldehyde, ketone, alcohol or hydrocarbon type.
Aromatic substance compounds of the ester type are, for example, benzyl acetate, phe- noxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethyl- benzylcarbinyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethylmethyl- phenyl glycinate, allylcyclohexyl propionate, styrallyl propionate and benzyl salicylate. The ethers include, for example, benzyl ethyl ether; the aldehydes include, for example, the linear alkanals having from 8 to 18 hydrocarbon atoms, citral, citronellal, citronellyl oxyacetal- dehyde, cyclamen aldehyde, hydroxycitronellal, lilial and bourgeonal; the ketones include, for example, the ionones, α-isomethylionone and methyl cedryl ketone; the alcohols include, for example, anethol, citronellol, eugenol, isoeugenol, geraniol, linalool, phenyl ethyl alcohol and terpinol; and the hydrocarbons include mainly the terpenes and balsams. It is preferable, however, to use mixtures of various aromatic substances that together produce an attractive scent. Ethereal oils of relatively low volatility, which are chiefly used as aroma components, are also suitable as perfume oils, e.g. sage oil, camomile oil, clove oil, melissa oil, oil of cinnamon leaves, lime blossom oil, juniper berry oil, vetiver oil, olibanum oil, gal- banum oil, labolanum oil and lavandin oil. Preference is given to the use of bergamot oil, di- hydromyrcenol, lilial, lyral, citronellol, phenyl ethyl alcohol, α-hexyl cinnamaldehyde, geraniol, benzyl acetone, cyclamen aldehyde, linalool, boisambrene forte, ambroxan, indole, he- dione, sandelice, lemon oil, tangerine oil, orange oil, allyl amyl glycolate, cyclovertal, lavandin oil, muscatel sage oil, β-damascone, bourbon geranium oil, cyclohexyl salicylate, ver- tofix coeur, iso-E-Super, Fixolide NP, evernyl, iraldein gamma, phenylacetic acid, geranyl acetate, benzyl acetate, rose oxide, romillat, irotyl and floramat alone or in admixture with one another.
There may be used as colourants the substances that are suitable and permitted for cosmetic purposes, as compiled, for example, in the publication "Kosmetische Farbemittel" of the Farbstoffkommission der Deutschen Forschungsgemeinschaft, Verlag Chemie, Weinheim, 1984, pages 81 to 106. The colourants are usually used in concentrations of from 0.001 to 0.1 % by weight, based on the total mixture.
Typical examples of bacteria-inhibiting agents are preservatives that have a specific action against gram-positive bacteria, such as 2,4,4'-trichIoro-2'-hydroxydiphenyl ether, chlor- hexidine (1,6-di(4-chlorophenyl-biguanido)hexane) or TCC (3,4,4'-trichlorocarbanilide). A large number of aromatic substances and ethereal oils also have antimicrobial properties. Typical examples are the active ingredients eugenol, menthol and thymol in clove oil, mint oil and thyme oil. A natural deodorising agent of interest is the terpene alcohol farnesol (3,7,1 1 -trimethyl-2,6,10-dodecatrien-1 -ol), which is present in lime blossom oil. Glycerol monolaurate has also proved to be a bacteriostatic agent. The amount of the additional bacteria-inhibiting agents present is usually from 0.1 to 2 % by weight, based on the solids content of the preparations.
It is furthermore possible for the cosmetic preparations to contain, as adjuvants, anti-foams, such as silicones, structurants, such as maleic acid, solubilisers, such as ethylene glycol, propylene glycol, glycerol or diethylene glycol, opacifiers, such as latex, styrene/PVP or sty- rene/acrylamide copolymers, complexing agents, such as EDTA, NTA, β-alaninediacetic acid or phosphonic acids, propellants, such as propane/butane mixtures, N20, dimethyl ether, CO2, N2 or air, so-called coupler and developer components as oxidation dye precursors, reducing agents, such as thioglycolic acid and derivatives thereof, thiolactic acid, cysteamine, thiomalic acid or α-mercaptoethanesulfonic acid, or oxidising agents, such as hydrogen peroxide, potassium bromate or sodium bromate.
There come into consideration as insect repellents, for example, N,N-diethyl-m-toluamide, 1 ,2-pentanediol or insect repellent 3535; suitable self-tanning agents are, for example, di- hydroxyacetone, erythrulose or mixtures of dihydroxyacetone and erythrulose.
Cosmetic formulations according to the invention are contained in a wide variety of cosmetic preparations. There come into consideration, for example, especially the following preparations: skin-care preparations, e.g. skin-washing and cleansing preparations in the form of tablet-form or liquid soaps, synthetic detergents or washing pastes, bath preparations, e.g. liquid (foam baths, milks, shower preparations) or solid bath preparations, e.g. bath cubes and bath salts; skin-care preparations, e.g. skin emulsions, multi-emulsions or skin oils; cosmetic personal care preparations, e.g. facial make-up in the form of day creams or powder creams, face powder (loose or pressed), rouge or cream make-up, eye-care preparations, e.g. eyeshadow preparations, mascara, eyeliner, eye creams or eye-fix creams; lip-care preparations, e.g. lipsticks, lip gloss, lip contour pencils, nail-care preparations, such as nail varnish, nail varnish removers, nail hardeners or cuticle removers; foot-care preparations, e.g. foot baths, foot powders, foot creams or foot balsams, special deodorants and antiperspirants or callus-removing preparations; light-protective preparations, such as sun milks, lotions, creams or oils, sunblocks or tropicals, pre-tanning preparations or after-sun preparations; skin-tanning preparations, e.g. self-tanning creams; depigmenting preparations, e.g. preparations for bleaching the skin or skin-lightening preparations; insect-repellents, e.g. insect-repellent oils, lotions, sprays or sticks; deodorants, such as deodorant sprays, pump-action sprays, deodorant gels, sticks or roll-ons; antiperspirants, e.g. antiperspirant sticks, creams or roll-ons; preparations for cleansing and caring for blemished skin, e.g. synthetic detergents (solid or liquid), peeling or scrub preparations or peeling masks; hair-removal preparations in chemical form (depilation), e.g. hair-removing powders, liquid hair-removing preparations, cream- or paste-form hair-removing preparations, hair-removing preparations in gel form or aerosol foams; shaving preparations, e.g. shaving soap, foaming shaving creams, non-foaming shaving creams, foams and gels, preshave preparations for dry shaving, aftershaves or aftershave lotions; fragrance preparations, e.g. fragrances (eau de Cologne, eau de toilette, eau de parfum, parfum de toilette, perfume), perfume oils or perfume creams; cosmetic hair-treatment preparations, e.g. hair-washing preparations in the form of shampoos and conditioners, hair-care preparations, e.g. pretreatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair-structuring preparations, e.g. hair-waving preparations for permanent waves (hot wave, mild wave, cold wave), hair-straightening preparations, liquid hair- setting preparations, hair foams, hairsprays, bleaching preparations, e.g. hydrogen peroxide solutions, lightening shampoos, bleaching creams, bleaching powders, bleaching pastes or oils, temporary, semi-permanent or permanent hair colourants, preparations containing self-oxidising dyes, or natural hair colourants, such as henna or camomile.
The final formulations listed may exist in a variety of presentation forms, for example:
- in the form of liquid preparations as a W/O, O/W, O/W/O, W/O/W or PIT emulsion and all kinds of microemulsions,
- in the form of a gel,
- in the form of an oil, a cream, milk or lotion,
- in the form of a powder, a lacquer, a tablet or make-up,
- in the form of a stick,
- in the form of a spray (spray with propellent gas or pump-action spray) or an aerosol,
- in the form of a foam, or
- in the form of a paste.
Of special importance as cosmetic preparations for the skin are light-protective preparations, such as sun milks, lotions, creams, oils, sunblocks or tropicals, pretanning preparations or after-sun preparations, also skin-tanning preparations, for example self-tanning creams. Of particular interest are sun protection creams, sun protection lotions, sun protection oils, sun protection milk and sun protection preparations in the form of a spray.
Of special importance as cosmetic preparations for the hair are the above-mentioned preparations for hair treatment, especially hair-washing preparations in the form of shampoos, hair conditioners, hair-care preparations, e.g. pretreatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair- straightening preparations, liquid hair-setting preparations, hair foams and hairsprays. Of special interest are hair-washing preparations in the form of shampoos.
A shampoo has, for example, the following composition: from 0.01 to 5 % by weight of a UV absorber according to the invention, 12.0 % by weight of sodium laureth-2-sulfate, 4.0 % by weight of cocamidopropyl betaine, 3.0 % by weight of sodium chloride, and water ad 100%. For example, especially the following hair-cosmetic formulations may be used: a,) spontaneously emulsifying stock formulation, consisting of the UV absorber according to the invention, PEG-6-C10oxoalcohol and sorbitan sesquioleate, to which water and any desired quaternary ammonium compound, for example 4 % minkamidopropyl dimethyl-2-hydroxyethylammonium chloride or Quaternium 80 is added; a2) spontaneously emulsifying stock formulation consisting of the UV absorber according to the invention, tributyl citrate and PEG-20-sorbitan monooleate, to which water and any desired quaternary ammonium compound, for example 4 % minkamidopropyl dimethyl-2-hydroxyethylammonium chloride or Quaternium 80 is added; b) Quat-doped solutions of the UV absorber according to the invention in butyl triglycol and tributyl citrate; c) mixtures or solutions of the UV absorber according to the invention with n-alkylpyrrolidone.
The cosmetic preparation according to the invention is distinguished by excellent protection of human skin against the damaging effect of sunlight. In the following Examples, percentages relate to weight. The amounts of the triazine derivatives used relate to the pure substance.
Preparation Examples of the novel compounds:
Example 1 :
A suspension of 7 g (0.05 mol) of dimedone and 14.8 g (0.1 mol) of orthoformic acid triethyl ester in 15 ml of isobutanol is maintained at reflux for 2 hours. After cooling to room temperature, 4.6 g (0.025 mol) of 2,4-diamino-6-phenyl-1,3,5-triazine and 3 drops of trifluoromethanesulfonic anhydride are added. The reaction mixture is maintained at reflux for 20 hours and then cooled to room temperature. The resulting crude product is filtered off. The colourless product is obtained by column chromatography (silica gel) using a 9:1 mixture of dichloromethane and methanol as eluant and is dried at 60°C in vacuo. Yield: 1 g (8 % of theory).
Figure imgf000037_0001
λma!t = 320 nm; ε = 50 970, E (= extinction value) (1 %, 1 cm) = 1045 γmax = 224 nm; ε= 35 699, E (1 %, 1 cm) = 732
Example 2:
0.1 ml of trifluoromethanesulfonic anhydride is added, at 90°C , to a solution of 7.5 g (0.05 mol) of orthoformic acid triethyl ester in 50 ml of isobutanol. 2.3 g (0.0125 mol) of 2,2-diamino-6-phenyl-1 ,3,5-triazine are then introduced in portions in the course of 1.5 hours. The resulting solution is stirred for 30 minutes at 100 °C. After the addition of 2.3 g (0.025 mol) of acetylacetone, the reaction mixture is maintained at reflux for 4 hours. After cooling to room temperature, the suspension is filtered. The filter cake is recrystallised from ethyl acetate and dried in vacuo at 70 °C. Yield: 1.3 g (26 % of theory).
Figure imgf000038_0001
λmax = 322 nm; ε = 42 906, E (1 %, 1 cm) = 1053 (in ethanol)
Example 3:
7.2 g (0.05 mol) of malonic acid cyclic isopropylidene ester, 14.8 g (0.1 mol) of orthoformic acid triethyl ester and 4.6 g (0.025 mol) of diaminophenyltriazine are mixed in 150 ml of toluene and then maintained at reflux for 1 hour. In the course of 2 hours, 2.5 g of phos- phoryl chloride are added dropwise and the reaction mixture is refluxed for a further
2 hours. After cooling to room temperature, 100 ml of water and 100 ml of ethyl acetate are added. The organic phase is separated off and heated for 30 minutes at 40-50 °C together with 5 g of sodium sulfate and 5 g of Tonsil. After filtration of the mixture while it is still warm, the filtrate is concentrated to dryness by evaporation. Subsequent column chroma- tography (silica gel) using a 7:3 mixture of toluene and acetone yields the pure product, which is dried in vacuo at 80 °C. Yield: 5 g (40 % of theory).
Figure imgf000038_0002
λmax = 332 nm; ε = 68 068, E (1 %, 1 cm) = 1 374 (in dioxane) Example 4:
In a sulfonating flask equipped with a reflux condensor and a calcium chloride drying tube, 4.78 g (0.025 mol) of 2,4-diamino-6-phenyl-1 ,3,5-triazine, 9.96 g (0.075 mol) of ethyl aceto-acetate, 8.12 g (0.075 mol) of orthoformic acid trimethyl ester and 1.03 g (0.006 mol) of copper(ll) chloride dihydrate are mixed in 50 ml of dimethylacetamide and stirred for 3 hours at 70 °C. After cooling to room temperature, the reaction mixture is stirred into 200 ml of 10 % sodium sulfate solution. The precipitate that forms is filtered off, washed neutral with water and recrystallised from ethanol. The product is dried in vacuo at 60 °C. Yield: 4.1 g (35 % of theory).
Figure imgf000039_0001
Yield: 4.1 g (35% of theory) λmax = 319 nm; ε = 45 969, E (1%, 1 cm) = 983 (in ethanol)
Example 5:
3.22 g (0.025 mol) of melamine, 14.94 g (0.1 125 mol) of ethyl acetoacetate, 12.18 g (0.1 125 mol) of orthoformic acid trimethyl ester and 1.03 g (0.006 mol) of copper(ll) chloride dihydrate are stirred in 50 ml of N-methylpyrrolidone for 4 hours at 80 °C. The cold reaction mixture is added to 400 ml of 5 % aqueous sodium sulfate solution. The resulting precipitate is filtered off, washed with water and recrystallised from ethanol. The product is dried in vacuo at 60 °C. Yield: 6.5 g (48 % of theory).
Figure imgf000040_0001
γmax = 325 nm; ε = 790448, E (1 %, 1 cm) = 1350 (in dioxane)
Example 6:
3.22 g (0.025 mol) of melamine, 16.60 g (0.113 mol) of malonic acid cyclic isopropylidene ester, 1 7.09 g (0.1 1 3 mol) of orthoformic acid triethyl ester and 1.03 g (0.006 mol) of cop- per(ll) chloride dihydrate are stirred in 50 ml of N-methylpyrrolidone for 6 hours at 80 °C. The cold reaction mixture is added to 400 ml of 5 % aqueous sodium sulfate solution. The resulting precipitate is filtered off, washed with water and copious amounts of ethanol. The product is dried in vacuo at 60 °C. Yield: 6.2 g (42 % of theory).
Figure imgf000040_0002
λmax = 326 nm; ε = 61 956, E (1 %, 1 cm) = 1053 (in dioxane) Example 6: Parallel syntheses of the compounds of the general formula
Figure imgf000041_0001
General procedure:
2,4-Diamino-6-phenyl-1 ,3,5-triazine (0.0013 mol, 0.24 g) is dissolved in N-methylpyrroIidone (1.15 ml). Orthoformic acid trimethyl ester (0.0038 mol, 0.42 ml), copper chloride dihydrate solution (0.001 3 mol, 0.22 g in 0.5 ml of NMP) and the appropriate ketone (0.0038 mol dissolved in 2 ml of NMP) are added to the solution. The reaction mixture is shaken for 4 hours at 70°C. The crude product is precipitated by the addition of 10 ml of 10 % aqueous sodium sulfate solution, and the precipitate is then filtered off and washed with copious amounts of ethanol. Subsequent column chromatography (Nucleosil 5C18) using a mixture of acetonitrile and water yields the pure product.
Example 7: Parallel syntheses of the compounds of formula
Figure imgf000041_0002
General procedure:
Melamine (0.0013 mol, 0.17 g) is dissolved in N-methylpyrrolidone (1.42 ml). Orthoformic acid trimethyl ester (0.0057 mol, 0.59 ml), copper chloride dihydrate solution (0.0013 mol, 0.22 g in 0.5 ml of NMP) and the appropriate ketone (0.0057 mol dissolved in 2 ml of NMP) are added to the solution. The reaction mixture is shaken for 4 hours at 80 °C. The crude product is precipitated by the addition of 10 ml of 10 % aqueous sodium sulfate solution, and the precipitate is then filtered off and washed with copious amounts of ethanol. Subsequent column chromatography (Nucleosil 5C18)) using a mixture of acetonitrile and water yields the pure product.
Example 8: Parallel syntheses of the compounds of formula
Figure imgf000042_0001
General procedure:
2,4-Diamino-6-p-methoxyphenyl-1 ,3,5-triazine (0.0005 mol, 0.1 1 g) is dissolved in N- methylpyrrolidone (0.6 ml). Orthoformic acid trimethyl ester (0.0013 mol, 0.14 g), copper chloride dihydrate solution (0.0013 mol, 0.22 g in 0.5 ml of NMP) and the appropriate ketone (0.0005 mol dissolved in 0.23 ml of NMP) are added to the solution. The reaction mixture is shaken for 4 hours at 80 °C. The crude product is precipitated by the addition of 10 ml of 10 % aqueous sodium sulfate solution, and the precipitate is then filtered off and washed with copious amounts of ethanol. Subsequent column chromatography (Nucleosil 5C18)) using a mixture of acetonitrile and water yields the pure product.
Example 9: Parallel syntheses of the compounds of formula
Figure imgf000042_0002
General procedure:
2,4-Diamino-6-methyl-1,3,5-triazine (0,0013 mol, 0.16 g) is dissolved in N-methylpyrroIidone (1.5 ml). Orthoformic acid trimethyl ester (0.0038 mol, 0.42 ml), copper chloride dihydrate solution (0.001 3 mol, 0.22 g in 0.5 ml of NMP) and the appropriate ketone (0.0038 mol dissolved in 2 ml of NMP) are added to the solution. The reaction mixture is shaken for 4 hours at 70°C. The crude product is precipitated by the addition of 10 ml of 10 % aqueous sodium sulfate solution, and the precipitate is then filtered off and washed with copious amounts of ethanol. Subsequent column chromatography (Nucleosil 5C18) using a mixture of acetonitrile and water yields the pure product.
Application Examples
Example 10: Sun Protection Lotion
Figure imgf000043_0001
This emulsion is easy to spread with good absorption properties. Manufacturing instruction:
Heat part A and B separately up to 75°C; part C to 60°C. Afterwards pour part B into part A under stirring. Homogenize with an Ultra Turrax for 30 sec. at 11 000 rpm and incorporate part C. Let cool down to 40°C and add part D. At room temperature adjust the pH-value with Sodium Hydroxide between 6.30 and 6.70 and add part F.
Example 1 1 : Sprayable Sunscreen Lotion
Figure imgf000044_0001
This emulsion contains a combination of insoluble UV-absorber. The choice of emollients provides quick absorption and smooth after skin feeling. Manufacturing instruction:
Heat part A and part B separately up to 80°C; part C to 50°C. Pour part B into part A and homogenize with an Ultra Turrax for 1 minute by 11000 rpm. After cooling down to 50°C add part C under continuous stirring. At 40°C incorporate part D and homogenize again for 10 sec. by 11000 rpm. Adjust the pH with part E.
Example 12: Sunscreen Lotion, water resistant
Figure imgf000045_0001
O/W emulsion with a soft touch and good rub in properties. Manufacturing instruction:
Heat part A and part B separately up to 75°C. Pour part B into part A under progressive stirring speed. Below 65°C add separately the ingredients of part D. Let cool down to 55°C under moderate stirring and add part C. Less than 35°C check and adjust the pH with Sodium Hydroxide and homogenize with an Ultra Turrax for 30 sec. at 1 1 000 rpm. At room temperature add part F.
Example 13:
Figure imgf000046_0001
This emulsion is smooth and spreads easily. The choice of mainly light emollients gives the lotion a light and non-tacky skin feeling. Manufacturing instruction:
Heat part A and part B separately up to 80°C. Pour part B into part A under moderate stirring. Homogenize with an Ultra Turrax at 11000 rpm for 1 minute. Let cool down to 70°C and add part C under stirring. Cool further down to 50°C and incorporate TINOSORB® M very slowly. At 40°C add part E. At room temperature adjust the pH with part F to 7.00 and add part G.
Example 14: O/W emulsion water resistant
Figure imgf000047_0001
Part F Fragrance qs
O/W emulsion with a soft touch and good rub in properties.
Manufacturing instruction:
Heat part A and part B separately up to 75CC. Pour part B into part A under progressive stirring speed. Below 65°C add separately the ingredients of part D. Let cool down to 55°C under moderate stirring and add part C. Less than 35°C check and adjust the pH with Sodium Hydroxide and homogenize with an Ultra Turrax for 30 sec. at 1 1 000 rpm. At room temperature add part F.
Example 14: Sun Protection Lotion. O/W type
Figure imgf000048_0001
This emulsion is smooth and spreads easily.
Manufacturing instruction:
Heat part A and part B separately up to 80°C. Pour part B into part A under moderate stirring. Homogenize with an Ultra Turrax at 11000 rpm for 1 minute. Let cool down to 70°C and add part C under stirring. Cool further down to 50°C and incorporate TINOSORB® M very slowly. At 40°C add part E. At room temperature adjust the pH with part F to 7.00 and add part G.

Claims

What is claimed is:
1. A compound of formula
Figure imgf000050_0001
wherein
R, is a C,-C18alkyl, C2-C18alkenyl, C6-C10aryl or C6-C10heteroaryl radical each unsubstituted or mono- or poly-substituted by hydroxy, C,-C18alkyl, C,-C18alkoxy, amino, C^Cjmonoalkyl- amino or by di-C,-C5alkylamino; C5-C7cycloalkyl or C5-C7cycloalkenyl each unsubstituted or substituted by C,-C5alkyl; -OR'; or -NR'R";
R2 is hydrogen; a C,-C18alkyl, C2-C18alkenyl, C6-C]0aryl or C6-C10heteroaryl radical each unsubstituted or mono- or poly-substituted by hydroxy, C^C^alkoxy, cyano, amino,
C^-C-monoalkylamino or by di-C,-C3alkylamino; -OR'; or -NR'R"; or
R, and R2 together form a 5- to 7-membered carbocyclic or heterocyclic ring;
A is C,-C5alkyl; an unsubstituted or hydroxy-, C,-C18alkyl- or C,-C18alkoxy-substituted
C6-C10aryl or heteroaryl radical; or a radical of formula (1 a) /
Figure imgf000050_0002
R' and R" are each independently of the other hydrogen; unsubstituted or mono- or poly- hydroxy-, halo-, C^C^alkyl-, C,-C18alkoxy-, amino- or quaternary ammonium group- substituted C,-C18alkyl, C5-C7cycloalkyl or phenyl;
R3 is hydrogen; or C^-C^alkyl; and n is 0 or 1.
2. A compound according to claim 1 , wherein R, and R2 are each independently of the other C,-C,8alkyl or phenyl each unsubstituted or substituted by C,-C5alkyl, hydroxy or by C,-C5alkoxy; -OR'; or -NR'R"; or R, and R2 together form a 5- to 7-membered carbocyclic or heterocyclic ring.
3. A compound according to either claim 1 or claim 2, wherein
R, is C,-C3alkyl; C^C-alkoxy; or unsubstituted or C,-C3alkyl-, hydroxy- or C C5alkoxy- substituted phenyl.
4. A compound according to any one of claims 1 to 3, wherein
R2 is hydrogen; C,-C5alkyl; C,-C5alkoxy; unsubstituted or hydroxy-, C,-C5alkyl- or C,-C5- alkoxy-substituted phenyl; and n is 1.
5. A compound according to either claim 1 or claim 2, wherein
R, and R2 together are a -(CH2)2.S- radical that is not further substituted or is substituted by one or more C,-C5alkyl and is uninterrupted or interrupted by one or two -O- and/or
-NH- groups and/or — c — . o
6. A compound according to claim 5, wherein
Figure imgf000051_0001
and
R5 is hydrogen; or C1-C5alkyl.
7. A compound according to any one of claims 1 to 6, wherein A is amino; phenyl; or C^-Cjalkoxyphenyl.
8. A compound according to any one of claims 1 to 7, wherein R3 is hydrogen.
9. A process for the preparation of a triazine derivative of formula (1 ) according to claim 1 , wherein the diaminotriazine compound of formula
(1 a) is reacted with a compound of formula (1b)
Figure imgf000052_0001
Figure imgf000052_0002
(1c) to form a compound of formula (1), wherein
Figure imgf000052_0003
R, is C,-C5alkyl and
R and R' are as defined for formula (1), to form a compound of formula (1).
10. Use of a triazine derivative of formula (1) according to claim 1 for the protection of human and animal hair and skin against the damaging effect of UV radiation.
11. Use according to claim 10, wherein the triazine derivative of formula (1 ) is present in micronised form.
12. A cosmetic preparation comprising at least one or more compounds of formula (1) according to claim 1 together with cosmetically tolerable carriers or adjuvants.
13. A preparation according to claim 12 that comprises further UV protective substances.
PCT/EP2002/008888 2001-08-17 2002-08-08 Triazine derivatives and their use as sunscreens WO2003016289A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT02772133T ATE485281T1 (en) 2001-08-17 2002-08-08 TRIAZINE DERIVATIVES AND THEIR USE AS SUNSCREEN
DK02772133.1T DK1423371T3 (en) 2001-08-17 2002-08-08 Triazine derivatives and their use as sun protection
JP2003521215A JP4344241B2 (en) 2001-08-17 2002-08-08 Triazine derivatives and their use as sunscreens
DE60238066T DE60238066D1 (en) 2001-08-17 2002-08-08 TRIAZINE DERIVATIVES AND THEIR USE AS SUN PROTECTION AGENTS
EP02772133A EP1423371B1 (en) 2001-08-17 2002-08-08 Triazine derivatives and their use as sunscreens
US10/486,761 US7038046B2 (en) 2001-08-17 2002-08-08 Triazine derivatives and their use as sunscreens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01810796.1 2001-08-17
EP01810796 2001-08-17
CH16992001 2001-09-14
CH1699/01 2001-09-14

Publications (1)

Publication Number Publication Date
WO2003016289A1 true WO2003016289A1 (en) 2003-02-27

Family

ID=25739004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008888 WO2003016289A1 (en) 2001-08-17 2002-08-08 Triazine derivatives and their use as sunscreens

Country Status (7)

Country Link
US (1) US7038046B2 (en)
EP (1) EP1423371B1 (en)
JP (1) JP4344241B2 (en)
AT (1) ATE485281T1 (en)
DE (1) DE60238066D1 (en)
DK (1) DK1423371T3 (en)
WO (1) WO2003016289A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867188A1 (en) * 2004-03-03 2005-09-09 Oreal New s-triazine derivatives containing p-oxyphenyl and aminobenzalmalonic acids, for use as broad-spectrum ultraviolet (UV) filters, especially in cosmetic or dermatological sunscreen compositions
WO2012091088A1 (en) * 2010-12-28 2012-07-05 日産化学工業株式会社 Coating solution for forming polyimide film, liquid crystal alignment agent, polyimide film, liquid crystal alignment film, and liquid crystal display element
WO2015003360A3 (en) * 2013-07-11 2015-03-12 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9434979B2 (en) 2009-10-21 2016-09-06 Shin-San Michael Su Methods and compositions for cell-proliferation-related disorders
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9512107B2 (en) 2012-01-06 2016-12-06 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9662327B2 (en) 2011-06-17 2017-05-30 Agios Pharmaceuticals, Inc Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
US9724350B2 (en) 2013-07-11 2017-08-08 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9856279B2 (en) 2011-06-17 2018-01-02 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US9980961B2 (en) 2011-05-03 2018-05-29 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
US10017495B2 (en) 2013-07-11 2018-07-10 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10029987B2 (en) 2009-06-29 2018-07-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US10202339B2 (en) 2012-10-15 2019-02-12 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US10610125B2 (en) 2009-03-13 2020-04-07 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
US10689414B2 (en) 2013-07-25 2020-06-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US11234976B2 (en) 2015-06-11 2022-02-01 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
US11419859B2 (en) 2015-10-15 2022-08-23 Servier Pharmaceuticals Llc Combination therapy for treating malignancies

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7574545B2 (en) * 2000-10-16 2009-08-11 Electronics For Imaging, Inc. Method and apparatus for controlling a document output device with a control request stored at a server
US6748471B1 (en) * 2000-10-16 2004-06-08 Electronics For Imaging, Inc. Methods and apparatus for requesting and receiving a print job via a printer polling device associated with a printer
US20070286827A1 (en) * 2006-06-12 2007-12-13 Esschem, Inc. Optical brighter and uv stabilizer for acrylic enhancements
EP2037746A4 (en) * 2006-06-29 2010-09-22 Martek Biosciences Corp Sweetened oil compositions and methods of making
JP5796931B2 (en) * 2006-08-24 2015-10-21 ユニリーバー・ナームローゼ・ベンノートシヤープ Light-stable cosmetic composition
US20080097070A1 (en) * 2006-10-19 2008-04-24 L'oreal Aqueous polyamine-containing systems for water-insoluble materials
US20080096782A1 (en) * 2006-10-19 2008-04-24 L'oreal Aqueous systems containing phospholipid, surfactant and phosphate ester for water-insoluble materials
CA2792018A1 (en) 2010-05-10 2011-11-17 Segetis, Inc. Fragrant formulations, methods of manufacture thereof and articles comprising the same
US9040030B2 (en) * 2010-12-30 2015-05-26 L'oreal Mascara compositions containing an oil-dispersible micronized wax and a water-dispersible wax
CN107827764A (en) * 2017-11-27 2018-03-23 上海应用技术大学 A kind of preparation method of double β amino ketones or double β amino esters

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105923A1 (en) * 1991-02-26 1992-08-27 Basf Ag New triazine derivs. carrying para-amino:cinnamic acid substit. - useful as protectant against light esp. in cosmetics
US5520906A (en) * 1992-02-19 1996-05-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Triazine derivatives with UV filter properties
US5928630A (en) * 1996-02-12 1999-07-27 Societe L' Oreal S.A. Benzalmalonate/phenylcyanoacrylate-substituted s-triazine compounds and photoprotective/cosmetic compositions comprised thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105923A1 (en) * 1991-02-26 1992-08-27 Basf Ag New triazine derivs. carrying para-amino:cinnamic acid substit. - useful as protectant against light esp. in cosmetics
US5520906A (en) * 1992-02-19 1996-05-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Triazine derivatives with UV filter properties
US5928630A (en) * 1996-02-12 1999-07-27 Societe L' Oreal S.A. Benzalmalonate/phenylcyanoacrylate-substituted s-triazine compounds and photoprotective/cosmetic compositions comprised thereof

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867188A1 (en) * 2004-03-03 2005-09-09 Oreal New s-triazine derivatives containing p-oxyphenyl and aminobenzalmalonic acids, for use as broad-spectrum ultraviolet (UV) filters, especially in cosmetic or dermatological sunscreen compositions
US10610125B2 (en) 2009-03-13 2020-04-07 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US10988448B2 (en) 2009-06-29 2021-04-27 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
USRE49582E1 (en) 2009-06-29 2023-07-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US10029987B2 (en) 2009-06-29 2018-07-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9434979B2 (en) 2009-10-21 2016-09-06 Shin-San Michael Su Methods and compositions for cell-proliferation-related disorders
US9982309B2 (en) 2009-10-21 2018-05-29 Agios Pharmaceuticals, Inc. Method for treating cell proliferation related disorders
US10711314B2 (en) 2009-10-21 2020-07-14 Agios Pharmaceuticals, Inc. Methods for diagnosing IDH-mutant cell proliferation disorders
WO2012091088A1 (en) * 2010-12-28 2012-07-05 日産化学工業株式会社 Coating solution for forming polyimide film, liquid crystal alignment agent, polyimide film, liquid crystal alignment film, and liquid crystal display element
KR101856808B1 (en) 2010-12-28 2018-05-10 닛산 가가쿠 고교 가부시키 가이샤 Coating solution for forming polyimide film, liquid crystal alignment agent, polyimide film, liquid crystal alignment film, and liquid crystal display element
US10632114B2 (en) 2011-05-03 2020-04-28 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
US9980961B2 (en) 2011-05-03 2018-05-29 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
US9662327B2 (en) 2011-06-17 2017-05-30 Agios Pharmaceuticals, Inc Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
US9856279B2 (en) 2011-06-17 2018-01-02 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US11505538B1 (en) 2012-01-06 2022-11-22 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
US9732062B2 (en) 2012-01-06 2017-08-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9656999B2 (en) 2012-01-06 2017-05-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9512107B2 (en) 2012-01-06 2016-12-06 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10294215B2 (en) 2012-01-06 2019-05-21 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10717764B2 (en) 2012-01-19 2020-07-21 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9850277B2 (en) 2012-01-19 2017-12-26 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10640534B2 (en) 2012-01-19 2020-05-05 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10202339B2 (en) 2012-10-15 2019-02-12 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US10111878B2 (en) 2013-07-11 2018-10-30 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9724350B2 (en) 2013-07-11 2017-08-08 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US10172864B2 (en) 2013-07-11 2019-01-08 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10028961B2 (en) 2013-07-11 2018-07-24 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A3 (en) * 2013-07-11 2015-03-12 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10017495B2 (en) 2013-07-11 2018-07-10 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10946023B2 (en) 2013-07-11 2021-03-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10689414B2 (en) 2013-07-25 2020-06-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US11021515B2 (en) 2013-07-25 2021-06-01 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10799490B2 (en) 2014-03-14 2020-10-13 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US10449184B2 (en) 2014-03-14 2019-10-22 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US11504361B2 (en) 2014-03-14 2022-11-22 Servier Pharmaceuticals Llc Pharmaceutical compositions of therapeutically active compounds
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US11234976B2 (en) 2015-06-11 2022-02-01 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
US11419859B2 (en) 2015-10-15 2022-08-23 Servier Pharmaceuticals Llc Combination therapy for treating malignancies
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Also Published As

Publication number Publication date
JP4344241B2 (en) 2009-10-14
EP1423371A1 (en) 2004-06-02
DK1423371T3 (en) 2011-02-07
US7038046B2 (en) 2006-05-02
US20040242579A1 (en) 2004-12-02
ATE485281T1 (en) 2010-11-15
JP2005501855A (en) 2005-01-20
EP1423371B1 (en) 2010-10-20
DE60238066D1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
EP1423371B1 (en) Triazine derivatives and their use as sunscreens
US7407648B2 (en) Merocyanine derivatives for cosmetic use
AU2003214092B2 (en) UV absorber compositions comprising a hydroxyphenyltriazine compound
AU2004206724B2 (en) Triazine derivatives as UV absorbers
GB2409203A (en) Merocyanine derivatives for cosmetic use
US20090068129A1 (en) Aminophenylbenzothiazole compounds
GB2458362A (en) Dimeric benzylidene malonates and derivatives thereof for use as UV-light absorbers in cosmetics
AU2002339555B2 (en) Use of guaiol for treating the skin
EP2616041B1 (en) Use of specific bis(biphenyl)triazine derivatives and mixtures thereof as uv absorbers
EP2629749B1 (en) Use of silane and siloxane bis(biphenyl)triazine derivatives as uv absorbers
EP2355791B1 (en) Benzylidene compounds comprising phosphono-groups
US7432400B2 (en) Biphenylene compounds
GB2438047A (en) Triazine derivatives as UV filters for cosmetic compositions
ES2354870T3 (en) DERIVATIVES OF TRIAZINE AND ITS USES AS SOLAR PROTECTORS.
AU2002333740A1 (en) Biphenylene compounds
GB2440638A (en) 2-(2'-Hydroxy-4'-aminophenyl)benzotriazoles as UV protecting agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002772133

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10486761

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003521215

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002772133

Country of ref document: EP